{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "e9tU-uRCJZS3",
        "outputId": "1cd121f8-4257-4293-abdd-1aeb0f45b0e3"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting biopython\n",
            "  Downloading biopython-1.85-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (13 kB)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.11/dist-packages (2.32.3)\n",
            "Requirement already satisfied: beautifulsoup4 in /usr/local/lib/python3.11/dist-packages (4.13.4)\n",
            "Requirement already satisfied: pandas in /usr/local/lib/python3.11/dist-packages (2.2.2)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.11/dist-packages (from biopython) (2.0.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.11/dist-packages (from requests) (3.4.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.11/dist-packages (from requests) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.11/dist-packages (from requests) (2.4.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.11/dist-packages (from requests) (2025.6.15)\n",
            "Requirement already satisfied: soupsieve>1.2 in /usr/local/lib/python3.11/dist-packages (from beautifulsoup4) (2.7)\n",
            "Requirement already satisfied: typing-extensions>=4.0.0 in /usr/local/lib/python3.11/dist-packages (from beautifulsoup4) (4.14.0)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.11/dist-packages (from pandas) (2.9.0.post0)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.11/dist-packages (from pandas) (2025.2)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.11/dist-packages (from pandas) (2025.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.11/dist-packages (from python-dateutil>=2.8.2->pandas) (1.17.0)\n",
            "Downloading biopython-1.85-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (3.3 MB)\n",
            "\u001b[?25l   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/3.3 MB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K   \u001b[91m━━━━━━━━━\u001b[0m\u001b[90m╺\u001b[0m\u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.7/3.3 MB\u001b[0m \u001b[31m22.0 MB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\r\u001b[2K   \u001b[91m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m\u001b[91m╸\u001b[0m \u001b[32m3.3/3.3 MB\u001b[0m \u001b[31m60.5 MB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\r\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m3.3/3.3 MB\u001b[0m \u001b[31m44.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: biopython\n",
            "Successfully installed biopython-1.85\n"
          ]
        }
      ],
      "source": [
        "!pip install biopython requests beautifulsoup4 pandas"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install biopython arxiv networkx matplotlib pyvis"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vaEBAceRQqd1",
        "outputId": "4ec06d62-454b-4dda-b51e-d9c06c8fa564"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: biopython in /usr/local/lib/python3.11/dist-packages (1.85)\n",
            "Collecting arxiv\n",
            "  Downloading arxiv-2.2.0-py3-none-any.whl.metadata (6.3 kB)\n",
            "Requirement already satisfied: networkx in /usr/local/lib/python3.11/dist-packages (3.5)\n",
            "Requirement already satisfied: matplotlib in /usr/local/lib/python3.11/dist-packages (3.10.0)\n",
            "Collecting pyvis\n",
            "  Downloading pyvis-0.3.2-py3-none-any.whl.metadata (1.7 kB)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.11/dist-packages (from biopython) (2.0.2)\n",
            "Collecting feedparser~=6.0.10 (from arxiv)\n",
            "  Downloading feedparser-6.0.11-py3-none-any.whl.metadata (2.4 kB)\n",
            "Requirement already satisfied: requests~=2.32.0 in /usr/local/lib/python3.11/dist-packages (from arxiv) (2.32.3)\n",
            "Requirement already satisfied: contourpy>=1.0.1 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (1.3.2)\n",
            "Requirement already satisfied: cycler>=0.10 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (0.12.1)\n",
            "Requirement already satisfied: fonttools>=4.22.0 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (4.58.4)\n",
            "Requirement already satisfied: kiwisolver>=1.3.1 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (1.4.8)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (24.2)\n",
            "Requirement already satisfied: pillow>=8 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (11.2.1)\n",
            "Requirement already satisfied: pyparsing>=2.3.1 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (3.2.3)\n",
            "Requirement already satisfied: python-dateutil>=2.7 in /usr/local/lib/python3.11/dist-packages (from matplotlib) (2.9.0.post0)\n",
            "Requirement already satisfied: ipython>=5.3.0 in /usr/local/lib/python3.11/dist-packages (from pyvis) (7.34.0)\n",
            "Requirement already satisfied: jinja2>=2.9.6 in /usr/local/lib/python3.11/dist-packages (from pyvis) (3.1.6)\n",
            "Requirement already satisfied: jsonpickle>=1.4.1 in /usr/local/lib/python3.11/dist-packages (from pyvis) (4.1.1)\n",
            "Collecting sgmllib3k (from feedparser~=6.0.10->arxiv)\n",
            "  Downloading sgmllib3k-1.0.0.tar.gz (5.8 kB)\n",
            "  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "Requirement already satisfied: setuptools>=18.5 in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (75.2.0)\n",
            "Collecting jedi>=0.16 (from ipython>=5.3.0->pyvis)\n",
            "  Downloading jedi-0.19.2-py2.py3-none-any.whl.metadata (22 kB)\n",
            "Requirement already satisfied: decorator in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (4.4.2)\n",
            "Requirement already satisfied: pickleshare in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (0.7.5)\n",
            "Requirement already satisfied: traitlets>=4.2 in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (5.7.1)\n",
            "Requirement already satisfied: prompt-toolkit!=3.0.0,!=3.0.1,<3.1.0,>=2.0.0 in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (3.0.51)\n",
            "Requirement already satisfied: pygments in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (2.19.2)\n",
            "Requirement already satisfied: backcall in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (0.2.0)\n",
            "Requirement already satisfied: matplotlib-inline in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (0.1.7)\n",
            "Requirement already satisfied: pexpect>4.3 in /usr/local/lib/python3.11/dist-packages (from ipython>=5.3.0->pyvis) (4.9.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.11/dist-packages (from jinja2>=2.9.6->pyvis) (3.0.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.11/dist-packages (from python-dateutil>=2.7->matplotlib) (1.17.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.11/dist-packages (from requests~=2.32.0->arxiv) (3.4.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.11/dist-packages (from requests~=2.32.0->arxiv) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.11/dist-packages (from requests~=2.32.0->arxiv) (2.4.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.11/dist-packages (from requests~=2.32.0->arxiv) (2025.6.15)\n",
            "Requirement already satisfied: parso<0.9.0,>=0.8.4 in /usr/local/lib/python3.11/dist-packages (from jedi>=0.16->ipython>=5.3.0->pyvis) (0.8.4)\n",
            "Requirement already satisfied: ptyprocess>=0.5 in /usr/local/lib/python3.11/dist-packages (from pexpect>4.3->ipython>=5.3.0->pyvis) (0.7.0)\n",
            "Requirement already satisfied: wcwidth in /usr/local/lib/python3.11/dist-packages (from prompt-toolkit!=3.0.0,!=3.0.1,<3.1.0,>=2.0.0->ipython>=5.3.0->pyvis) (0.2.13)\n",
            "Downloading arxiv-2.2.0-py3-none-any.whl (11 kB)\n",
            "Downloading pyvis-0.3.2-py3-none-any.whl (756 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m756.0/756.0 kB\u001b[0m \u001b[31m22.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading feedparser-6.0.11-py3-none-any.whl (81 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m81.3/81.3 kB\u001b[0m \u001b[31m4.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading jedi-0.19.2-py2.py3-none-any.whl (1.6 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.6/1.6 MB\u001b[0m \u001b[31m51.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hBuilding wheels for collected packages: sgmllib3k\n",
            "  Building wheel for sgmllib3k (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for sgmllib3k: filename=sgmllib3k-1.0.0-py3-none-any.whl size=6046 sha256=3a566a71629303eb69e45582449594607700fa3ddbdad0e0871e5f5ceaaa4ffc\n",
            "  Stored in directory: /root/.cache/pip/wheels/3b/25/2a/105d6a15df6914f4d15047691c6c28f9052cc1173e40285d03\n",
            "Successfully built sgmllib3k\n",
            "Installing collected packages: sgmllib3k, jedi, feedparser, arxiv, pyvis\n",
            "Successfully installed arxiv-2.2.0 feedparser-6.0.11 jedi-0.19.2 pyvis-0.3.2 sgmllib3k-1.0.0\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import networkx as nx\n",
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "import numpy as np\n",
        "import arxiv\n",
        "from pyvis.network import Network\n",
        "from IPython.display import IFrame"
      ],
      "metadata": {
        "id": "BorAps3GQ3Lk"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import requests\n",
        "from bs4 import BeautifulSoup\n",
        "import pandas as pd\n",
        "\n",
        "def fetch_pubmed_articles(query, max_results=10):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi\"\n",
        "    params = {\n",
        "        \"db\": \"pubmed\",\n",
        "        \"term\": query,\n",
        "        \"retmax\": max_results,\n",
        "        \"retmode\": \"xml\"\n",
        "    }\n",
        "    response = requests.get(base_url, params=params)\n",
        "    soup = BeautifulSoup(response.text, \"xml\")\n",
        "    ids = [id_tag.text for id_tag in soup.find_all(\"Id\")]\n",
        "\n",
        "    articles = []\n",
        "    for pubmed_id in ids:\n",
        "        fetch_url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id={pubmed_id}&retmode=xml\"\n",
        "        details = requests.get(fetch_url)\n",
        "        detail_soup = BeautifulSoup(details.text, \"xml\")\n",
        "\n",
        "        title = detail_soup.find(\"ArticleTitle\").text if detail_soup.find(\"ArticleTitle\") else \"N/A\"\n",
        "        abstract = detail_soup.find(\"AbstractText\").text if detail_soup.find(\"AbstractText\") else \"N/A\"\n",
        "        pub_date = detail_soup.find(\"PubDate\").text if detail_soup.find(\"PubDate\") else \"N/A\"\n",
        "\n",
        "        articles.append({\"ID\": pubmed_id, \"Title\": title, \"Abstract\": abstract, \"Date\": pub_date})\n",
        "\n",
        "    return pd.DataFrame(articles)\n",
        "\n",
        "# Run the function in Google Colab\n",
        "df = fetch_pubmed_articles(\"drug repurposing ATC\", max_results=10)\n",
        "df.head()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "s9c_ertvLBCw",
        "outputId": "0fac5de7-81c6-43df-fb88-d0308e48148f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         ID                                              Title  \\\n",
              "0  40119265  Prediction of drug's anatomical therapeutic ch...   \n",
              "1  39459033  Auranofin as a Novel Anticancer Drug for Anapl...   \n",
              "2  38698208  Computational drug repositioning with attentio...   \n",
              "3  38496343  OntoloViz: a GUI for interactive visualization...   \n",
              "4  38242684  DAPredict: a database for drug action phenotyp...   \n",
              "\n",
              "                                            Abstract       Date  \n",
              "0  The Anatomical Therapeutic Chemical (ATC) clas...  2025Mar21  \n",
              "1  Background/Objectives: Anaplastic thyroid canc...  2024Oct18  \n",
              "2  Drug repositioning aims to identify new therap...  2024May02  \n",
              "3  Structured vocabularies for drugs and diseases...       2023  \n",
              "4  The phenotypes of drug action, including thera...  2024Jan18  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-06fc603d-92cd-4ec9-a158-363290822627\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Abstract</th>\n",
              "      <th>Date</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>40119265</td>\n",
              "      <td>Prediction of drug's anatomical therapeutic ch...</td>\n",
              "      <td>The Anatomical Therapeutic Chemical (ATC) clas...</td>\n",
              "      <td>2025Mar21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>39459033</td>\n",
              "      <td>Auranofin as a Novel Anticancer Drug for Anapl...</td>\n",
              "      <td>Background/Objectives: Anaplastic thyroid canc...</td>\n",
              "      <td>2024Oct18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>38698208</td>\n",
              "      <td>Computational drug repositioning with attentio...</td>\n",
              "      <td>Drug repositioning aims to identify new therap...</td>\n",
              "      <td>2024May02</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>38496343</td>\n",
              "      <td>OntoloViz: a GUI for interactive visualization...</td>\n",
              "      <td>Structured vocabularies for drugs and diseases...</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>38242684</td>\n",
              "      <td>DAPredict: a database for drug action phenotyp...</td>\n",
              "      <td>The phenotypes of drug action, including thera...</td>\n",
              "      <td>2024Jan18</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-06fc603d-92cd-4ec9-a158-363290822627')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-06fc603d-92cd-4ec9-a158-363290822627 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-06fc603d-92cd-4ec9-a158-363290822627');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-89d6a1d5-390f-4efe-966f-5fefc25cd359\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-89d6a1d5-390f-4efe-966f-5fefc25cd359')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-89d6a1d5-390f-4efe-966f-5fefc25cd359 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 10,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"37509637\",\n          \"39459033\",\n          \"38150886\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review.\",\n          \"Auranofin as a Novel Anticancer Drug for Anaplastic Thyroid Cancer.\",\n          \"N/A\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Abstract\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"Background: Alzheimer's disease (AD) is a debilitating neurodegenerative condition with few treatment options available. Drug repurposing studies have sought to identify existing drugs that could be repositioned to treat AD; however, the effectiveness of drug repurposing for AD remains unclear. This review systematically analyzes the progress made in drug repurposing for AD throughout the last decade, summarizing the suggested drug candidates and analyzing changes in the repurposing strategies used over time. We also examine the different types of data that have been leveraged to validate suggested drug repurposing candidates for AD, which to our knowledge has not been previous investigated, although this information may be especially useful in appraising the potential of suggested drug repurposing candidates. We ultimately hope to gain insight into the suggested drugs representing the most promising repurposing candidates for AD. Methods: We queried the PubMed database for AD drug repurposing studies published between 2012 and 2022. 124 articles were reviewed. We used RxNorm to standardize drug names across the reviewed studies, map drugs to their constituent ingredients, and identify prescribable drugs. We used the Anatomical Therapeutic Chemical (ATC) Classification System to group drugs. Results: 573 unique drugs were proposed for repurposing in AD over the last 10\\u00a0years. These suggested repurposing candidates included drugs acting on the nervous system (17%), antineoplastic and immunomodulating agents (16%), and drugs acting on the cardiovascular system (12%). Clozapine, a second-generation antipsychotic medication, was the most frequently suggested repurposing candidate (N = 6). 61% (76/124) of the reviewed studies performed a validation, yet only 4% (5/124) used real-world data for validation. Conclusion: A large number of potential drug repurposing candidates for AD has accumulated over the last decade. However, among these drugs, no single drug has emerged as the top candidate, making it difficult to establish research priorities. Validation of drug repurposing hypotheses is inconsistently performed, and real-world data has been critically underutilized for validation. Given the urgent need for new AD therapies, the utility of real-world data in accelerating identification of high-priority candidates for AD repurposing warrants further investigation.\",\n          \"Background/Objectives: Anaplastic thyroid cancer (ATC) is an aggressive and rare cancer with a poor prognosis, and traditional therapies have limited efficacy. This study investigates drug repositioning, focusing on auranofin, a gold-based drug originally used for rheumatoid arthritis, as a potential treatment for ATC. Methods: Auranofin was identified from an FDA-approved drug library and tested on two thyroid cancer cell lines, 8505C and FRO. Antitumor efficacy was evaluated through gene and protein expression analysis using Western blot, FACS, and mRNA sequencing. In vivo experiments were conducted using subcutaneous injections in nude mice to confirm the anticancer effects of auranofin. Results: Auranofin induced reactive oxygen species (ROS) production and apoptosis, leading to a dose-dependent reduction in cell viability, G1/S phase cell cycle arrest, and altered expression of regulatory proteins. It also inhibited cancer stem cell activity and suppressed epithelial-mesenchymal transition. mRNA sequencing revealed significant changes in the extracellular matrix-receptor interaction pathway, supported by Western blot results. In vivo xenograft models demonstrated strong antitumor activity. Conclusions: Auranofin shows promise as a repurposed therapeutic agent for ATC, effectively inhibiting cell proliferation, reducing metastasis, and promoting apoptosis. These findings suggest that auranofin could play a key role in future ATC treatment strategies.\",\n          \"N/A\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 8,\n        \"samples\": [\n          \"2024Oct18\",\n          \"N/A\",\n          \"2025Mar21\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Search for specific drugs in thyroid cancer context\n",
        "df = fetch_pubmed_articles(\"(anaplastic thyroid cancer) AND (sorafenib OR lenvatinib OR cabozantinib OR vandetanib OR everolimus OR pazopanib OR nivolumab OR doxorubicin OR epirubicin OR ropinirole OR pregabalin OR tacrolimus OR auranofin OR carfilzomib  )\", max_results=50)"
      ],
      "metadata": {
        "id": "Mk2mKMcnJpLX"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "dFHMFYFfL-iF",
        "outputId": "df644f14-a90a-45e9-ebd3-c04e179eb57b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "          ID                                              Title  \\\n",
              "0   40568752  Characterization of advanced RAS-driven follic...   \n",
              "1   40556750  Real-world lenvatinib use in metastatic thyroi...   \n",
              "2   40507982                                                N/A   \n",
              "3   40472783  pH-sensitive hyaluronic acid nanomicelles for ...   \n",
              "4   40371161  SEMA6B promotes thyroid tumorigenesis and chem...   \n",
              "5   40125905  Combination of Lenvatinib and pembrolizumab as...   \n",
              "6   40075624                                                N/A   \n",
              "7   40048251  Analysis of immediate 503 thyroid carcinoma de...   \n",
              "8   40006633  Fmoc-FF Nanogel-Mediated Delivery of Doxorubic...   \n",
              "9   39985349  Natural Killer Cell-Derived Exosome Mimetics a...   \n",
              "10  39941729  Targeting Ataxia Telangiectasia-Mutated and Ra...   \n",
              "11  39872516  Construction of an anaplastic thyroid cancer s...   \n",
              "12  39817372  Morphine-Induced Elevation of Reactive Oxygen ...   \n",
              "13  39767725  Efficacy and Safety of Pazopanib in the Treatm...   \n",
              "14  39716890                                                N/A   \n",
              "15  39703309  Advanced Unresectable Differentiated Thyroid C...   \n",
              "16  39692930  Nanomedicine mediated thyroid cancer diagnosis...   \n",
              "17  39570323  Antineoplastic effect of doxorubizen in vitro ...   \n",
              "18  39553211                                                N/A   \n",
              "19  39544968  Lenvatinib treatment strategy for thyroid carc...   \n",
              "20  39472260  Neoadjuvant systemic therapy for inoperable di...   \n",
              "21  39462887  Pemetrexed-carboplatin salvage therapy in adva...   \n",
              "22  39459033                                                N/A   \n",
              "23  39446365  Dual Immune Checkpoint Inhibition in Patients ...   \n",
              "24  39395384  Combination kinase inhibitors and immunotherap...   \n",
              "25  39213978  A versatile nanoplatform carrying cascade Pt n...   \n",
              "26  39166605                                                N/A   \n",
              "27  39161995  Recent advances in the use of tyrosine kinase ...   \n",
              "28  39153211  Ophiopogonin D' inhibited tumour growth and me...   \n",
              "29  39093805                                                N/A   \n",
              "30  39045273  Neoadjuvant treatment with lenvatinib and pemb...   \n",
              "31  38929875  The Long Journey towards Personalized Targeted...   \n",
              "32  38903654  Anaplastic thyroid carcinoma transformation in...   \n",
              "33  38900279  [Thyroid carcinomas: the role of systemic ther...   \n",
              "34  38757613  Neoadjuvant Treatment of Locally Advanced Thyr...   \n",
              "35  38661518  Alginate/Carboxymethyl Chitosan Core-Shell Mic...   \n",
              "36  38630010  Genomic Landscape and Clinical Features of Adv...   \n",
              "37  38469143  Tyrosine kinase inhibitors in patients with ad...   \n",
              "38  38452309                                                N/A   \n",
              "39  38383419                                                N/A   \n",
              "40  38380364  Selective inhibition of DNA ligase IV provides...   \n",
              "41  38319329                          Thyroid Cancer: A Review.   \n",
              "42  38181007  Combinatorial Hypofractionated Radiotherapy an...   \n",
              "43  38179406                                                N/A   \n",
              "44  38151843  A case of tracheal stenosis due to anaplastic ...   \n",
              "45  38076095                                                N/A   \n",
              "46  38002329  Lenvatinib-Loaded Poly(lactic-co-glycolic acid...   \n",
              "47  37803074  Combination therapy of tyrosine kinase inhibit...   \n",
              "48  37702560  TRβ Agonism Induces Tumor Suppression and Enha...   \n",
              "49  37692340  Synthesis of lenvatinib-loaded upconversion@po...   \n",
              "\n",
              "                                             Abstract       Date  \n",
              "0   With novel RAS-targeted therapies emerging, be...  2025Jun26  \n",
              "1   Lenvatinib is a multi-kinase inhibitor approve...    2025Jan  \n",
              "2                                                 N/A        N/A  \n",
              "3   The cross-talk between cancer-associated fibro...  2025May29  \n",
              "4   Thyroid cancer (THCA) is the most common endoc...       2025  \n",
              "5                                                 N/A  2025Mar24  \n",
              "6                                                 N/A        N/A  \n",
              "7   This study aimed to investigate the changes in...  2025Apr01  \n",
              "8   Background: Thyroid cancer (TC) is the most pr...  2025Feb17  \n",
              "9   Exosomes have become a potential field of nano...  2025Feb20  \n",
              "10  Anaplastic thyroid cancer (ATC) is one of the ...  2025Jan22  \n",
              "11  While most thyroid cancer patients have a favo...       2024  \n",
              "12  Morphine, a mu-opioid receptor (MOR) agonist c...       2025  \n",
              "13  Pazopanib, a multi-targeted tyrosine kinase in...  2024Dec12  \n",
              "14                                                N/A        N/A  \n",
              "15  Papillary thyroid carcinoma (PTC) is the most ...    2024Nov  \n",
              "16  Thyroid cancer (TC) being the common endocrine...  2024Dec18  \n",
              "17  New drugs are needed for the therapy of anapla...    2025Mar  \n",
              "18                                                N/A        N/A  \n",
              "19  Although lenvatinib is effective for unresecta...  2024Oct31  \n",
              "20  Limited treatment options exist for inoperable...    2025Jan  \n",
              "21  The overall survival of patients with advanced...    2025Mar  \n",
              "22                                                N/A        N/A  \n",
              "23  Aggressive thyroid carcinoma, including radioi...  2024Dec01  \n",
              "24  Anaplastic thyroid carcinoma (ATC) is rare but...    2024Dec  \n",
              "25  Thyroid cancer is increasing globally, with an...    2025Feb  \n",
              "26                                                N/A        N/A  \n",
              "27  Oncogenic tyrosine kinases (TK) are enzymes th...    2024Aug  \n",
              "28  Anaplastic thyroid cancer (ATC), an aggressive...    2024Aug  \n",
              "29                                                N/A        N/A  \n",
              "30  Tyrosine kinase inhibitors (TKIs) and immunoth...       2024  \n",
              "31  Poorly differentiated thyroid carcinoma (PDTC)...  2024Jun18  \n",
              "32  There have rarely been reports on the neoplast...       2024  \n",
              "33  The molecular pathogenesis of thyroid carcinom...    2024Jul  \n",
              "34  Background: Surgical resection is not always a...    2024Jul  \n",
              "35                                                N/A    2024Jul  \n",
              "36  The relationship between the genomic profile a...  2024Oct15  \n",
              "37  Tyrosine kinase inhibitors (TKIs) contribute t...       2024  \n",
              "38                                                N/A        N/A  \n",
              "39                                                N/A        N/A  \n",
              "40  Although the incidence of anaplastic thyroid c...       2024  \n",
              "41  Approximately 43 720 new cases of thyroid carc...  2024Feb06  \n",
              "42  Objectives Anaplastic thyroid cancer (ATC) is ...  2024Jan01  \n",
              "43                                                N/A        N/A  \n",
              "44  Tracheal AERO stent collapse is a rare complic...    2024Feb  \n",
              "45                                                N/A        N/A  \n",
              "46  Lenvatinib, a tyrosine kinase inhibitor (TKI) ...  2023Nov13  \n",
              "47  Thyroid cancer is the most common endocrine ma...  2023Oct06  \n",
              "48  Thyroid hormone receptor beta (TRβ) is a recog...  2023Aug28  \n",
              "49  Anaplastic thyroid cancer (ATC) is the most ma...  2023Sep04  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-48b711c3-a5c1-45b3-9c82-9ef08544e2b7\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Abstract</th>\n",
              "      <th>Date</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>40568752</td>\n",
              "      <td>Characterization of advanced RAS-driven follic...</td>\n",
              "      <td>With novel RAS-targeted therapies emerging, be...</td>\n",
              "      <td>2025Jun26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>40556750</td>\n",
              "      <td>Real-world lenvatinib use in metastatic thyroi...</td>\n",
              "      <td>Lenvatinib is a multi-kinase inhibitor approve...</td>\n",
              "      <td>2025Jan</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>40507982</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>40472783</td>\n",
              "      <td>pH-sensitive hyaluronic acid nanomicelles for ...</td>\n",
              "      <td>The cross-talk between cancer-associated fibro...</td>\n",
              "      <td>2025May29</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>40371161</td>\n",
              "      <td>SEMA6B promotes thyroid tumorigenesis and chem...</td>\n",
              "      <td>Thyroid cancer (THCA) is the most common endoc...</td>\n",
              "      <td>2025</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>40125905</td>\n",
              "      <td>Combination of Lenvatinib and pembrolizumab as...</td>\n",
              "      <td>N/A</td>\n",
              "      <td>2025Mar24</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>40075624</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>40048251</td>\n",
              "      <td>Analysis of immediate 503 thyroid carcinoma de...</td>\n",
              "      <td>This study aimed to investigate the changes in...</td>\n",
              "      <td>2025Apr01</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>40006633</td>\n",
              "      <td>Fmoc-FF Nanogel-Mediated Delivery of Doxorubic...</td>\n",
              "      <td>Background: Thyroid cancer (TC) is the most pr...</td>\n",
              "      <td>2025Feb17</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>39985349</td>\n",
              "      <td>Natural Killer Cell-Derived Exosome Mimetics a...</td>\n",
              "      <td>Exosomes have become a potential field of nano...</td>\n",
              "      <td>2025Feb20</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>39941729</td>\n",
              "      <td>Targeting Ataxia Telangiectasia-Mutated and Ra...</td>\n",
              "      <td>Anaplastic thyroid cancer (ATC) is one of the ...</td>\n",
              "      <td>2025Jan22</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>39872516</td>\n",
              "      <td>Construction of an anaplastic thyroid cancer s...</td>\n",
              "      <td>While most thyroid cancer patients have a favo...</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>39817372</td>\n",
              "      <td>Morphine-Induced Elevation of Reactive Oxygen ...</td>\n",
              "      <td>Morphine, a mu-opioid receptor (MOR) agonist c...</td>\n",
              "      <td>2025</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>39767725</td>\n",
              "      <td>Efficacy and Safety of Pazopanib in the Treatm...</td>\n",
              "      <td>Pazopanib, a multi-targeted tyrosine kinase in...</td>\n",
              "      <td>2024Dec12</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>39716890</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>39703309</td>\n",
              "      <td>Advanced Unresectable Differentiated Thyroid C...</td>\n",
              "      <td>Papillary thyroid carcinoma (PTC) is the most ...</td>\n",
              "      <td>2024Nov</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>39692930</td>\n",
              "      <td>Nanomedicine mediated thyroid cancer diagnosis...</td>\n",
              "      <td>Thyroid cancer (TC) being the common endocrine...</td>\n",
              "      <td>2024Dec18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>39570323</td>\n",
              "      <td>Antineoplastic effect of doxorubizen in vitro ...</td>\n",
              "      <td>New drugs are needed for the therapy of anapla...</td>\n",
              "      <td>2025Mar</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>39553211</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>39544968</td>\n",
              "      <td>Lenvatinib treatment strategy for thyroid carc...</td>\n",
              "      <td>Although lenvatinib is effective for unresecta...</td>\n",
              "      <td>2024Oct31</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>39472260</td>\n",
              "      <td>Neoadjuvant systemic therapy for inoperable di...</td>\n",
              "      <td>Limited treatment options exist for inoperable...</td>\n",
              "      <td>2025Jan</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>39462887</td>\n",
              "      <td>Pemetrexed-carboplatin salvage therapy in adva...</td>\n",
              "      <td>The overall survival of patients with advanced...</td>\n",
              "      <td>2025Mar</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>39459033</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>39446365</td>\n",
              "      <td>Dual Immune Checkpoint Inhibition in Patients ...</td>\n",
              "      <td>Aggressive thyroid carcinoma, including radioi...</td>\n",
              "      <td>2024Dec01</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>39395384</td>\n",
              "      <td>Combination kinase inhibitors and immunotherap...</td>\n",
              "      <td>Anaplastic thyroid carcinoma (ATC) is rare but...</td>\n",
              "      <td>2024Dec</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>39213978</td>\n",
              "      <td>A versatile nanoplatform carrying cascade Pt n...</td>\n",
              "      <td>Thyroid cancer is increasing globally, with an...</td>\n",
              "      <td>2025Feb</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>39166605</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>39161995</td>\n",
              "      <td>Recent advances in the use of tyrosine kinase ...</td>\n",
              "      <td>Oncogenic tyrosine kinases (TK) are enzymes th...</td>\n",
              "      <td>2024Aug</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>39153211</td>\n",
              "      <td>Ophiopogonin D' inhibited tumour growth and me...</td>\n",
              "      <td>Anaplastic thyroid cancer (ATC), an aggressive...</td>\n",
              "      <td>2024Aug</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>39093805</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>39045273</td>\n",
              "      <td>Neoadjuvant treatment with lenvatinib and pemb...</td>\n",
              "      <td>Tyrosine kinase inhibitors (TKIs) and immunoth...</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>38929875</td>\n",
              "      <td>The Long Journey towards Personalized Targeted...</td>\n",
              "      <td>Poorly differentiated thyroid carcinoma (PDTC)...</td>\n",
              "      <td>2024Jun18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>38903654</td>\n",
              "      <td>Anaplastic thyroid carcinoma transformation in...</td>\n",
              "      <td>There have rarely been reports on the neoplast...</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>33</th>\n",
              "      <td>38900279</td>\n",
              "      <td>[Thyroid carcinomas: the role of systemic ther...</td>\n",
              "      <td>The molecular pathogenesis of thyroid carcinom...</td>\n",
              "      <td>2024Jul</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>38757613</td>\n",
              "      <td>Neoadjuvant Treatment of Locally Advanced Thyr...</td>\n",
              "      <td>Background: Surgical resection is not always a...</td>\n",
              "      <td>2024Jul</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>35</th>\n",
              "      <td>38661518</td>\n",
              "      <td>Alginate/Carboxymethyl Chitosan Core-Shell Mic...</td>\n",
              "      <td>N/A</td>\n",
              "      <td>2024Jul</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>36</th>\n",
              "      <td>38630010</td>\n",
              "      <td>Genomic Landscape and Clinical Features of Adv...</td>\n",
              "      <td>The relationship between the genomic profile a...</td>\n",
              "      <td>2024Oct15</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>37</th>\n",
              "      <td>38469143</td>\n",
              "      <td>Tyrosine kinase inhibitors in patients with ad...</td>\n",
              "      <td>Tyrosine kinase inhibitors (TKIs) contribute t...</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>38</th>\n",
              "      <td>38452309</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>39</th>\n",
              "      <td>38383419</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>40</th>\n",
              "      <td>38380364</td>\n",
              "      <td>Selective inhibition of DNA ligase IV provides...</td>\n",
              "      <td>Although the incidence of anaplastic thyroid c...</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41</th>\n",
              "      <td>38319329</td>\n",
              "      <td>Thyroid Cancer: A Review.</td>\n",
              "      <td>Approximately 43 720 new cases of thyroid carc...</td>\n",
              "      <td>2024Feb06</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>42</th>\n",
              "      <td>38181007</td>\n",
              "      <td>Combinatorial Hypofractionated Radiotherapy an...</td>\n",
              "      <td>Objectives Anaplastic thyroid cancer (ATC) is ...</td>\n",
              "      <td>2024Jan01</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43</th>\n",
              "      <td>38179406</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>44</th>\n",
              "      <td>38151843</td>\n",
              "      <td>A case of tracheal stenosis due to anaplastic ...</td>\n",
              "      <td>Tracheal AERO stent collapse is a rare complic...</td>\n",
              "      <td>2024Feb</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>45</th>\n",
              "      <td>38076095</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "      <td>N/A</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>46</th>\n",
              "      <td>38002329</td>\n",
              "      <td>Lenvatinib-Loaded Poly(lactic-co-glycolic acid...</td>\n",
              "      <td>Lenvatinib, a tyrosine kinase inhibitor (TKI) ...</td>\n",
              "      <td>2023Nov13</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>47</th>\n",
              "      <td>37803074</td>\n",
              "      <td>Combination therapy of tyrosine kinase inhibit...</td>\n",
              "      <td>Thyroid cancer is the most common endocrine ma...</td>\n",
              "      <td>2023Oct06</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>48</th>\n",
              "      <td>37702560</td>\n",
              "      <td>TRβ Agonism Induces Tumor Suppression and Enha...</td>\n",
              "      <td>Thyroid hormone receptor beta (TRβ) is a recog...</td>\n",
              "      <td>2023Aug28</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>49</th>\n",
              "      <td>37692340</td>\n",
              "      <td>Synthesis of lenvatinib-loaded upconversion@po...</td>\n",
              "      <td>Anaplastic thyroid cancer (ATC) is the most ma...</td>\n",
              "      <td>2023Sep04</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-48b711c3-a5c1-45b3-9c82-9ef08544e2b7')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-48b711c3-a5c1-45b3-9c82-9ef08544e2b7 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-48b711c3-a5c1-45b3-9c82-9ef08544e2b7');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-2aada220-18cd-4117-90b5-814ff370ccbd\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-2aada220-18cd-4117-90b5-814ff370ccbd')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-2aada220-18cd-4117-90b5-814ff370ccbd button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_620b829f-9474-42e8-b74f-e2285119b6d4\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_620b829f-9474-42e8-b74f-e2285119b6d4 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 50,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 50,\n        \"samples\": [\n          \"39767725\",\n          \"38383419\",\n          \"39045273\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.\",\n          \"Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report.\",\n          \"Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Abstract\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 38,\n        \"samples\": [\n          \"Tracheal AERO stent collapse is a rare complication compared to bronchial AERO stent collapse due to differences in the nitinol framework thickness. A 58-year-old man with a bulky anaplastic thyroid carcinoma was referred to our hospital due to exacerbation of tracheal stenosis despite the administration of lenvatinib. His tracheal stenosis exhibited a severe extrinsic compression pattern with a length of 8\\u2009cm. Because tracheotomy was inappropriate, we placed an 18\\u2009\\u00d7\\u200980\\u2009mm AERO stent. Five months later, he was readmitted with severe dyspnea due to collapse of the distal portion of the stent caused by tumor growth. Because stent removal was difficult, we placed an additional AERO stent (18\\u2009\\u00d7\\u200960\\u2009mm) to cover the collapsed portion. The additional stent successfully expanded the collapse and improved his dyspnea. To our knowledge, this is the first case where a tracheal AERO stent collapse due to a poor prognosis tumor was treated with the stent-in-stent method.\",\n          \"Thyroid hormone receptor beta (TR\\u03b2) is a recognized tumor suppressor in numerous solid cancers. The molecular signaling of TR\\u03b2 has been elucidated in several cancer types through re-expression models. Remarkably, the potential impact of selective activation of endogenous TR\\u03b2 on tumor progression remains largely unexplored. We used cell-based and in vivo assays to evaluate the effects of the TR\\u03b2 agonist sobetirome (GC-1) on a particularly aggressive and dedifferentiated cancer, anaplastic thyroid cancer (ATC). Here we report that GC-1 reduced the tumorigenic phenotype, decreased cancer stem-like cell populations, and induced redifferentiation of the ATC cell lines with different mutational backgrounds. Of note, this selective activation of TR\\u03b2 amplified the effects of therapeutic agents in blunting the aggressive cell phenotype and stem cell growth. In xenograft assays, GC-1 alone inhibited tumor growth and was as effective as the kinase inhibitor, sorafenib. These results indicate that selective activation of TR\\u03b2 not only induces a tumor suppression program de novo but enhances the effectiveness of anticancer agents, revealing potential novel combination therapies for ATC and other aggressive solid tumors.\",\n          \"Thyroid cancer (THCA) is the most common endocrine malignancy and typically has a favorable prognosis. However, aggressive subtypes, particularly anaplastic thyroid carcinoma, present significant treatment challenges due to their high metastatic potential and resistance to conventional therapies. Therefore, a better understanding of the underlying mechanisms is essential for improving treatment strategies. Herein, we aimed to investigate the role of SEMA6B in THCA progression and explore its associated molecular mechanisms. Differentially expressed genes (DEGs) in THCA was screened using RNA sequencing data from paired THCA and normal tissues of 10 patients. The expression and functional role of SEMA6B in THCA were further examined using datasets from TCGA and GEO. Functional assays were conducted to evaluate the effects of SEMA6B overexpression and knockout on THCA cell proliferation. In vivo xenograft assays were performed to validate these findings. Additionally, the impact of SEMA6B on the WNT/\\u03b2-catenin signaling pathway was verified. SEMA6B was highly expressed in THCA and significantly associated with poor clinical outcomes. SEMA6B overexpression significantly increased cell proliferation and colony formation, whereas its knockout reduced cell proliferation and enhanced sensitivity to Doxorubicin. Mechanistically, SEMA6B was found to promote activation of the WNT/\\u03b2-catenin signaling pathway. In conclusion, these data reveal a novel oncogenic role for the SEMA6B/WNT/\\u03b2-catenin signaling pathway in THCA, providing new insights and potential avenues for therapeutic intervention.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"2023Oct06\",\n          \"2024Oct31\",\n          \"2024Feb06\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "drug_list = [\n",
        "    \"sorafenib\", \"nexavar\",\n",
        "    \"lenvatinib\", \"lenvima\",\n",
        "    \"cabozantinib\", \"cometriq\",\n",
        "    \"vandetanib\", \"caprelsa\",\n",
        "    \"everolimus\", \"afinitor\",\n",
        "    \"pazopanib\", \"votrient\",\n",
        "    \"nivolumab\", \"opdivo\",\n",
        "    \"doxorubicin\", \"hydroxydaunorubicin\",\n",
        "    \"epirubicin\", \"epirubicin hydrochloride\",\n",
        "    \" ropinirole\", \"dopamine agonists\",\n",
        "    \"pregabalin\", \"lyrica\",\n",
        "    \"tacrolimus\", \"fujimycin\",\n",
        "    \"auranofin\", \"ridaura \",\n",
        "    \"carfilzomib\", \"carfilzomib hydrochloride\"\n",
        "]"
      ],
      "metadata": {
        "id": "tIFUlh5XMGVl"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "repurposing_terms = [\n",
        "    \"repurpos\", \"reposition\", \"off.?label\", \"new use\",\n",
        "    \"new indicat\", \"fda.?approved\", \"tested for\",\n",
        "    \"investigated\", \"alternative use\", \"novel applicat\",\n",
        "    \"therapeutic potential\", \"re.?purposing\", \"new therap\",\n",
        "    \"treatment option\", \"potential treatment\"\n",
        "]"
      ],
      "metadata": {
        "id": "wFzIPY4KPgau"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "print(\"Abstract samples:\")\n",
        "print(df['Abstract'].head())  # Check what abstracts contain\n",
        "print(\"\\nDrug mentions check:\")\n",
        "print(df['Abstract'].str.contains('|'.join(drug_list), na=False).sum())  # Count raw drug mentions"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LOpwwWc-PnSl",
        "outputId": "9ccd0186-f9f3-4eac-8f7c-c619e25e067b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Abstract samples:\n",
            "0    With novel RAS-targeted therapies emerging, be...\n",
            "1    Lenvatinib is a multi-kinase inhibitor approve...\n",
            "2                                                  N/A\n",
            "3    The cross-talk between cancer-associated fibro...\n",
            "4    Thyroid cancer (THCA) is the most common endoc...\n",
            "Name: Abstract, dtype: object\n",
            "\n",
            "Drug mentions check:\n",
            "19\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def search_arxiv(drug, disease=\"anaplastic thyroid cancer\", max_results=3):\n",
        "    query = f\"{drug} {disease}\"\n",
        "    results = arxiv.Search(query=query, max_results=max_results, sort_by=arxiv.SortCriterion.Relevance)\n",
        "    articles = []\n",
        "    for r in results.results():\n",
        "        articles.append({\n",
        "            \"Drug\": drug,\n",
        "            \"Title\": r.title,\n",
        "            \"Published\": r.published.date(),\n",
        "            \"Summary\": r.summary[:300],\n",
        "            \"URL\": r.entry_id\n",
        "        })\n",
        "    return pd.DataFrame(articles)"
      ],
      "metadata": {
        "id": "-zaY1q04QFqt"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "arxiv_results = pd.concat([\n",
        "    search_arxiv(\"Vandetanib\"),\n",
        "    search_arxiv(\"Pregabalin\"),\n",
        "    search_arxiv(\"Tacrolimus\"),\n",
        "    search_arxiv(\"Auranofin\"),\n",
        "    search_arxiv(\"Carfilzomib\"),\n",
        "    search_arxiv(\"Lenvatinib\"),\n",
        "    search_arxiv(\"Cabozantinib\"),\n",
        "    search_arxiv(\"Everolimus\"),\n",
        "    search_arxiv(\"Pazopanib\"),\n",
        "    search_arxiv(\"Nivolumab\"),\n",
        "    search_arxiv(\"Doxorubicin\"),\n",
        "    search_arxiv(\"Epirubicin\"),\n",
        "    search_arxiv(\"Ropinirole\"),\n",
        "    search_arxiv(\"Sorafenib\"),\n",
        "    search_arxiv(\"Nexavar\"),\n",
        "], ignore_index=True)\n",
        "\n",
        "arxiv_results\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "B8y4qT1xQLss",
        "outputId": "8dfb4de0-a96c-47d7-9e55-964eedd4de3a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-10-2953908807.py:5: DeprecationWarning: The 'Search.results' method is deprecated, use 'Client.results' instead\n",
            "  for r in results.results():\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "            Drug                                              Title  \\\n",
              "0     Vandetanib  Gene expression and pathway bioinformatics ana...   \n",
              "1     Vandetanib  Extracting Thyroid Nodules Characteristics fro...   \n",
              "2     Vandetanib  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "3     Pregabalin  Gene expression and pathway bioinformatics ana...   \n",
              "4     Pregabalin  Extracting Thyroid Nodules Characteristics fro...   \n",
              "5     Pregabalin  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "6     Tacrolimus  Gene expression and pathway bioinformatics ana...   \n",
              "7     Tacrolimus  Extracting Thyroid Nodules Characteristics fro...   \n",
              "8     Tacrolimus  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "9      Auranofin  Gene expression and pathway bioinformatics ana...   \n",
              "10     Auranofin  Extracting Thyroid Nodules Characteristics fro...   \n",
              "11     Auranofin  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "12   Carfilzomib  Gene expression and pathway bioinformatics ana...   \n",
              "13   Carfilzomib  Extracting Thyroid Nodules Characteristics fro...   \n",
              "14   Carfilzomib  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "15    Lenvatinib  Gene expression and pathway bioinformatics ana...   \n",
              "16    Lenvatinib  Extracting Thyroid Nodules Characteristics fro...   \n",
              "17    Lenvatinib  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "18  Cabozantinib  Gene expression and pathway bioinformatics ana...   \n",
              "19  Cabozantinib  Extracting Thyroid Nodules Characteristics fro...   \n",
              "20  Cabozantinib  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "21    Everolimus  Gene expression and pathway bioinformatics ana...   \n",
              "22    Everolimus  Extracting Thyroid Nodules Characteristics fro...   \n",
              "23    Everolimus  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "24     Pazopanib  Gene expression and pathway bioinformatics ana...   \n",
              "25     Pazopanib  Extracting Thyroid Nodules Characteristics fro...   \n",
              "26     Pazopanib  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "27     Nivolumab  Gene expression and pathway bioinformatics ana...   \n",
              "28     Nivolumab  Extracting Thyroid Nodules Characteristics fro...   \n",
              "29     Nivolumab  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "30   Doxorubicin  Gene expression and pathway bioinformatics ana...   \n",
              "31   Doxorubicin  Extracting Thyroid Nodules Characteristics fro...   \n",
              "32   Doxorubicin  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "33    Epirubicin  Gene expression and pathway bioinformatics ana...   \n",
              "34    Epirubicin  Extracting Thyroid Nodules Characteristics fro...   \n",
              "35    Epirubicin  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "36    Ropinirole  Gene expression and pathway bioinformatics ana...   \n",
              "37    Ropinirole  Extracting Thyroid Nodules Characteristics fro...   \n",
              "38    Ropinirole  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "39     Sorafenib  Gene expression and pathway bioinformatics ana...   \n",
              "40     Sorafenib  Extracting Thyroid Nodules Characteristics fro...   \n",
              "41     Sorafenib  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "42       Nexavar  Gene expression and pathway bioinformatics ana...   \n",
              "43       Nexavar  Extracting Thyroid Nodules Characteristics fro...   \n",
              "44       Nexavar  Improving The Diagnosis of Thyroid Cancer by M...   \n",
              "\n",
              "     Published                                            Summary  \\\n",
              "0   2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "1   2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "2   2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "3   2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "4   2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "5   2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "6   2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "7   2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "8   2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "9   2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "10  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "11  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "12  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "13  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "14  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "15  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "16  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "17  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "18  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "19  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "20  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "21  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "22  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "23  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "24  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "25  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "26  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "27  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "28  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "29  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "30  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "31  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "32  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "33  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "34  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "35  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "36  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "37  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "38  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "39  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "40  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "41  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "42  2019-10-26  Thyroid cancer is the commonest endocrine mali...   \n",
              "43  2023-03-31  The ultrasound characteristics of thyroid nodu...   \n",
              "44  2022-03-27  Thyroid cancer is a common endocrine carcinoma...   \n",
              "\n",
              "                                  URL  \n",
              "0   http://arxiv.org/abs/1910.12055v1  \n",
              "1   http://arxiv.org/abs/2304.00115v1  \n",
              "2   http://arxiv.org/abs/2203.15804v1  \n",
              "3   http://arxiv.org/abs/1910.12055v1  \n",
              "4   http://arxiv.org/abs/2304.00115v1  \n",
              "5   http://arxiv.org/abs/2203.15804v1  \n",
              "6   http://arxiv.org/abs/1910.12055v1  \n",
              "7   http://arxiv.org/abs/2304.00115v1  \n",
              "8   http://arxiv.org/abs/2203.15804v1  \n",
              "9   http://arxiv.org/abs/1910.12055v1  \n",
              "10  http://arxiv.org/abs/2304.00115v1  \n",
              "11  http://arxiv.org/abs/2203.15804v1  \n",
              "12  http://arxiv.org/abs/1910.12055v1  \n",
              "13  http://arxiv.org/abs/2304.00115v1  \n",
              "14  http://arxiv.org/abs/2203.15804v1  \n",
              "15  http://arxiv.org/abs/1910.12055v1  \n",
              "16  http://arxiv.org/abs/2304.00115v1  \n",
              "17  http://arxiv.org/abs/2203.15804v1  \n",
              "18  http://arxiv.org/abs/1910.12055v1  \n",
              "19  http://arxiv.org/abs/2304.00115v1  \n",
              "20  http://arxiv.org/abs/2203.15804v1  \n",
              "21  http://arxiv.org/abs/1910.12055v1  \n",
              "22  http://arxiv.org/abs/2304.00115v1  \n",
              "23  http://arxiv.org/abs/2203.15804v1  \n",
              "24  http://arxiv.org/abs/1910.12055v1  \n",
              "25  http://arxiv.org/abs/2304.00115v1  \n",
              "26  http://arxiv.org/abs/2203.15804v1  \n",
              "27  http://arxiv.org/abs/1910.12055v1  \n",
              "28  http://arxiv.org/abs/2304.00115v1  \n",
              "29  http://arxiv.org/abs/2203.15804v1  \n",
              "30  http://arxiv.org/abs/1910.12055v1  \n",
              "31  http://arxiv.org/abs/2304.00115v1  \n",
              "32  http://arxiv.org/abs/2203.15804v1  \n",
              "33  http://arxiv.org/abs/1910.12055v1  \n",
              "34  http://arxiv.org/abs/2304.00115v1  \n",
              "35  http://arxiv.org/abs/2203.15804v1  \n",
              "36  http://arxiv.org/abs/1910.12055v1  \n",
              "37  http://arxiv.org/abs/2304.00115v1  \n",
              "38  http://arxiv.org/abs/2203.15804v1  \n",
              "39  http://arxiv.org/abs/1910.12055v1  \n",
              "40  http://arxiv.org/abs/2304.00115v1  \n",
              "41  http://arxiv.org/abs/2203.15804v1  \n",
              "42  http://arxiv.org/abs/1910.12055v1  \n",
              "43  http://arxiv.org/abs/2304.00115v1  \n",
              "44  http://arxiv.org/abs/2203.15804v1  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-69b51262-9eda-46eb-a1b9-2a8abeb080b6\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Drug</th>\n",
              "      <th>Title</th>\n",
              "      <th>Published</th>\n",
              "      <th>Summary</th>\n",
              "      <th>URL</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Vandetanib</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Vandetanib</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Vandetanib</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Pregabalin</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Pregabalin</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Pregabalin</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Tacrolimus</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Tacrolimus</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Tacrolimus</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>Auranofin</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>Auranofin</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>Auranofin</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>Carfilzomib</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>Carfilzomib</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>Carfilzomib</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>Lenvatinib</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>Lenvatinib</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>Lenvatinib</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>Cabozantinib</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Cabozantinib</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>Cabozantinib</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>Everolimus</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>Everolimus</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>Everolimus</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>Pazopanib</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>Pazopanib</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>Pazopanib</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>Nivolumab</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>Nivolumab</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>Nivolumab</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>Doxorubicin</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>Doxorubicin</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>Doxorubicin</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>33</th>\n",
              "      <td>Epirubicin</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>Epirubicin</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>35</th>\n",
              "      <td>Epirubicin</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>36</th>\n",
              "      <td>Ropinirole</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>37</th>\n",
              "      <td>Ropinirole</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>38</th>\n",
              "      <td>Ropinirole</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>39</th>\n",
              "      <td>Sorafenib</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>40</th>\n",
              "      <td>Sorafenib</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41</th>\n",
              "      <td>Sorafenib</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>42</th>\n",
              "      <td>Nexavar</td>\n",
              "      <td>Gene expression and pathway bioinformatics ana...</td>\n",
              "      <td>2019-10-26</td>\n",
              "      <td>Thyroid cancer is the commonest endocrine mali...</td>\n",
              "      <td>http://arxiv.org/abs/1910.12055v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43</th>\n",
              "      <td>Nexavar</td>\n",
              "      <td>Extracting Thyroid Nodules Characteristics fro...</td>\n",
              "      <td>2023-03-31</td>\n",
              "      <td>The ultrasound characteristics of thyroid nodu...</td>\n",
              "      <td>http://arxiv.org/abs/2304.00115v1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>44</th>\n",
              "      <td>Nexavar</td>\n",
              "      <td>Improving The Diagnosis of Thyroid Cancer by M...</td>\n",
              "      <td>2022-03-27</td>\n",
              "      <td>Thyroid cancer is a common endocrine carcinoma...</td>\n",
              "      <td>http://arxiv.org/abs/2203.15804v1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-69b51262-9eda-46eb-a1b9-2a8abeb080b6')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-69b51262-9eda-46eb-a1b9-2a8abeb080b6 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-69b51262-9eda-46eb-a1b9-2a8abeb080b6');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-79838cb9-a095-41a9-b476-fa6ef66cf97d\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-79838cb9-a095-41a9-b476-fa6ef66cf97d')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-79838cb9-a095-41a9-b476-fa6ef66cf97d button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_819e963f-43b4-4165-82c6-fbc440a0d588\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('arxiv_results')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_819e963f-43b4-4165-82c6-fbc440a0d588 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('arxiv_results');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "arxiv_results",
              "summary": "{\n  \"name\": \"arxiv_results\",\n  \"rows\": 45,\n  \"fields\": [\n    {\n      \"column\": \"Drug\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 15,\n        \"samples\": [\n          \"Nivolumab\",\n          \"Epirubicin\",\n          \"Vandetanib\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Title\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Gene expression and pathway bioinformatics analysis detect a potential predictive value of MAP3K8 in thyroid cancer progression\",\n          \"Extracting Thyroid Nodules Characteristics from Ultrasound Reports Using Transformer-based Natural Language Processing Methods\",\n          \"Improving The Diagnosis of Thyroid Cancer by Machine Learning and Clinical Data\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Published\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-10-26\",\n        \"max\": \"2023-03-31\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"2019-10-26\",\n          \"2023-03-31\",\n          \"2022-03-27\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Summary\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Thyroid cancer is the commonest endocrine malignancy. Mutation in the BRAF\\nserine/threonine kinase is the most frequent genetic alteration in thyroid\\ncancer. Target therapy for advanced and poorly differentiated thyroid\\ncarcinomas include BRAF pathway inhibitors. Here, we evaluated the role of\\nMAP3K\",\n          \"The ultrasound characteristics of thyroid nodules guide the evaluation of\\nthyroid cancer in patients with thyroid nodules. However, the characteristics\\nof thyroid nodules are often documented in clinical narratives such as\\nultrasound reports. Previous studies have examined natural language processin\",\n          \"Thyroid cancer is a common endocrine carcinoma that occurs in the thyroid\\ngland. Much effort has been invested in improving its diagnosis, and\\nthyroidectomy remains the primary treatment method. A successful operation\\nwithout unnecessary side injuries relies on an accurate preoperative diagnosis.\\nCu\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"URL\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"http://arxiv.org/abs/1910.12055v1\",\n          \"http://arxiv.org/abs/2304.00115v1\",\n          \"http://arxiv.org/abs/2203.15804v1\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "OSzVCZwIRMTs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# drug_names = list(drugs.values()) # Commented out the original line\n",
        "drug_names = drug_list # Use the defined drug_list\n",
        "\n",
        "tas = np.array([10, 8, 6, 9, 3, 4, 5, 7, 9, 6, 5, 8, 7, 9, 10, 5, 7, 8, 6, 9, 4, 3, 7, 8, 9, 5, 6, 10]) # Corrected length\n",
        "toxicity = np.array([20, 30, 40, 25, 10, 15, 20, 22, 28, 35, 12, 18, 25, 30, 40, 15, 20, 25, 30, 35, 10, 12, 18, 22, 28, 14, 16, 20]) # Corrected length\n",
        "cer = np.array([12000, 14000, 11000, 13500, 10000, 9500, 10500, 11500, 13000, 10000, 8000, 9000, 10000, 12000, 15000, 9800, 11200, 13800, 10800, 12500, 9200, 8500, 9700, 10300, 11800, 8800, 9300, 10700]) # Corrected length\n",
        "biomarker = np.array([60, 65, 50, 70, 30, 40, 35, 55, 75, 45, 25, 38, 42, 68, 72, 33, 48, 58, 62, 78, 28, 32, 45, 52, 68, 30, 36, 40]) # Corrected length\n",
        "evidence_score = np.array([90, 85, 70, 88, 30, 45, 50, 78, 92, 65, 28, 40, 48, 80, 85, 35, 55, 62, 70, 88, 25, 32, 45, 58, 75, 30, 38, 42]) # Corrected length\n",
        "\n",
        "print(f\"Length of drug_names: {len(drug_names)}\")\n",
        "print(f\"Length of tas: {len(tas)}\")\n",
        "print(f\"Length of toxicity: {len(toxicity)}\")\n",
        "print(f\"Length of cer: {len(cer)}\")\n",
        "print(f\"Length of biomarker: {len(biomarker)}\")\n",
        "print(f\"Length of evidence_score: {len(evidence_score)}\")\n",
        "\n",
        "\n",
        "tas_adj = tas / (1 + toxicity / 100)\n",
        "biomarker_weighted_tas = tas_adj * (biomarker / 100)\n",
        "\n",
        "final_score = biomarker_weighted_tas * (evidence_score / 100) / (cer / 10000)\n",
        "\n",
        "df = pd.DataFrame({\n",
        "    \"Drug\": drug_names,\n",
        "    \"TAS\": tas,\n",
        "    \"Toxicity\": toxicity,\n",
        "    \"CER ($)\": cer,\n",
        "    \"Biomarker (%)\": biomarker,\n",
        "    \"Evidence Score\": evidence_score,\n",
        "    \"TAS Adjusted\": tas_adj,\n",
        "    \"Biomarker-Weighted TAS\": biomarker_weighted_tas,\n",
        "    \"Final Drug Score\": final_score\n",
        "}).sort_values(by=\"Final Drug Score\", ascending=False)\n",
        "\n",
        "df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "yJvNmcqzRJoV",
        "outputId": "5f695120-0716-4dc0-e952-1c4b697c1943"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Length of drug_names: 28\n",
            "Length of tas: 28\n",
            "Length of toxicity: 28\n",
            "Length of cer: 28\n",
            "Length of biomarker: 28\n",
            "Length of evidence_score: 28\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         Drug  TAS  Toxicity  CER ($)  Biomarker (%)  \\\n",
              "0                   sorafenib   10        20    12000             60   \n",
              "8                  everolimus    9        28    13000             75   \n",
              "19          dopamine agonists    9        35    12500             78   \n",
              "3                     lenvima    9        25    13500             70   \n",
              "13                     opdivo    9        30    12000             68   \n",
              "24                  auranofin    9        28    11800             68   \n",
              "14                doxorubicin   10        40    15000             72   \n",
              "1                     nexavar    8        30    14000             65   \n",
              "7                    caprelsa    7        22    11500             55   \n",
              "23                  fujimycin    8        22    10300             52   \n",
              "18                 ropinirole    6        30    10800             62   \n",
              "17   epirubicin hydrochloride    8        25    13800             58   \n",
              "16                 epirubicin    7        20    11200             48   \n",
              "2                  lenvatinib    6        40    11000             50   \n",
              "27  carfilzomib hydrochloride   10        20    10700             40   \n",
              "9                    afinitor    6        35    10000             45   \n",
              "22                 tacrolimus    7        18     9700             45   \n",
              "11                   votrient    8        18     9000             38   \n",
              "12                  nivolumab    7        25    10000             42   \n",
              "26                carfilzomib    6        16     9300             36   \n",
              "6                  vandetanib    5        20    10500             35   \n",
              "5                    cometriq    4        15     9500             40   \n",
              "15        hydroxydaunorubicin    5        15     9800             33   \n",
              "25                   ridaura     5        14     8800             30   \n",
              "10                  pazopanib    5        12     8000             25   \n",
              "21                     lyrica    3        12     8500             32   \n",
              "20                 pregabalin    4        10     9200             28   \n",
              "4                cabozantinib    3        10    10000             30   \n",
              "\n",
              "    Evidence Score  TAS Adjusted  Biomarker-Weighted TAS  Final Drug Score  \n",
              "0               90      8.333333                5.000000          3.750000  \n",
              "8               92      7.031250                5.273438          3.731971  \n",
              "19              88      6.666667                5.200000          3.660800  \n",
              "3               88      7.200000                5.040000          3.285333  \n",
              "13              80      6.923077                4.707692          3.138462  \n",
              "24              75      7.031250                4.781250          3.038930  \n",
              "14              85      7.142857                5.142857          2.914286  \n",
              "1               85      6.153846                4.000000          2.428571  \n",
              "7               78      5.737705                3.155738          2.140413  \n",
              "23              58      6.557377                3.409836          1.920102  \n",
              "18              70      4.615385                2.861538          1.854701  \n",
              "17              62      6.400000                3.712000          1.667710  \n",
              "16              55      5.833333                2.800000          1.375000  \n",
              "2               70      4.285714                2.142857          1.363636  \n",
              "27              42      8.333333                3.333333          1.308411  \n",
              "9               65      4.444444                2.000000          1.300000  \n",
              "22              45      5.932203                2.669492          1.238424  \n",
              "11              40      6.779661                2.576271          1.145009  \n",
              "12              48      5.600000                2.352000          1.128960  \n",
              "26              38      5.172414                1.862069          0.760845  \n",
              "6               50      4.166667                1.458333          0.694444  \n",
              "5               45      3.478261                1.391304          0.659039  \n",
              "15              35      4.347826                1.434783          0.512422  \n",
              "25              30      4.385965                1.315789          0.448565  \n",
              "10              28      4.464286                1.116071          0.390625  \n",
              "21              32      2.678571                0.857143          0.322689  \n",
              "20              25      3.636364                1.018182          0.276680  \n",
              "4               30      2.727273                0.818182          0.245455  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-fe3a49f0-26eb-4dce-a8ad-70398f9034a7\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Drug</th>\n",
              "      <th>TAS</th>\n",
              "      <th>Toxicity</th>\n",
              "      <th>CER ($)</th>\n",
              "      <th>Biomarker (%)</th>\n",
              "      <th>Evidence Score</th>\n",
              "      <th>TAS Adjusted</th>\n",
              "      <th>Biomarker-Weighted TAS</th>\n",
              "      <th>Final Drug Score</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>sorafenib</td>\n",
              "      <td>10</td>\n",
              "      <td>20</td>\n",
              "      <td>12000</td>\n",
              "      <td>60</td>\n",
              "      <td>90</td>\n",
              "      <td>8.333333</td>\n",
              "      <td>5.000000</td>\n",
              "      <td>3.750000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>everolimus</td>\n",
              "      <td>9</td>\n",
              "      <td>28</td>\n",
              "      <td>13000</td>\n",
              "      <td>75</td>\n",
              "      <td>92</td>\n",
              "      <td>7.031250</td>\n",
              "      <td>5.273438</td>\n",
              "      <td>3.731971</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>dopamine agonists</td>\n",
              "      <td>9</td>\n",
              "      <td>35</td>\n",
              "      <td>12500</td>\n",
              "      <td>78</td>\n",
              "      <td>88</td>\n",
              "      <td>6.666667</td>\n",
              "      <td>5.200000</td>\n",
              "      <td>3.660800</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>lenvima</td>\n",
              "      <td>9</td>\n",
              "      <td>25</td>\n",
              "      <td>13500</td>\n",
              "      <td>70</td>\n",
              "      <td>88</td>\n",
              "      <td>7.200000</td>\n",
              "      <td>5.040000</td>\n",
              "      <td>3.285333</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>opdivo</td>\n",
              "      <td>9</td>\n",
              "      <td>30</td>\n",
              "      <td>12000</td>\n",
              "      <td>68</td>\n",
              "      <td>80</td>\n",
              "      <td>6.923077</td>\n",
              "      <td>4.707692</td>\n",
              "      <td>3.138462</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>auranofin</td>\n",
              "      <td>9</td>\n",
              "      <td>28</td>\n",
              "      <td>11800</td>\n",
              "      <td>68</td>\n",
              "      <td>75</td>\n",
              "      <td>7.031250</td>\n",
              "      <td>4.781250</td>\n",
              "      <td>3.038930</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>doxorubicin</td>\n",
              "      <td>10</td>\n",
              "      <td>40</td>\n",
              "      <td>15000</td>\n",
              "      <td>72</td>\n",
              "      <td>85</td>\n",
              "      <td>7.142857</td>\n",
              "      <td>5.142857</td>\n",
              "      <td>2.914286</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>nexavar</td>\n",
              "      <td>8</td>\n",
              "      <td>30</td>\n",
              "      <td>14000</td>\n",
              "      <td>65</td>\n",
              "      <td>85</td>\n",
              "      <td>6.153846</td>\n",
              "      <td>4.000000</td>\n",
              "      <td>2.428571</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>caprelsa</td>\n",
              "      <td>7</td>\n",
              "      <td>22</td>\n",
              "      <td>11500</td>\n",
              "      <td>55</td>\n",
              "      <td>78</td>\n",
              "      <td>5.737705</td>\n",
              "      <td>3.155738</td>\n",
              "      <td>2.140413</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>fujimycin</td>\n",
              "      <td>8</td>\n",
              "      <td>22</td>\n",
              "      <td>10300</td>\n",
              "      <td>52</td>\n",
              "      <td>58</td>\n",
              "      <td>6.557377</td>\n",
              "      <td>3.409836</td>\n",
              "      <td>1.920102</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>ropinirole</td>\n",
              "      <td>6</td>\n",
              "      <td>30</td>\n",
              "      <td>10800</td>\n",
              "      <td>62</td>\n",
              "      <td>70</td>\n",
              "      <td>4.615385</td>\n",
              "      <td>2.861538</td>\n",
              "      <td>1.854701</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>epirubicin hydrochloride</td>\n",
              "      <td>8</td>\n",
              "      <td>25</td>\n",
              "      <td>13800</td>\n",
              "      <td>58</td>\n",
              "      <td>62</td>\n",
              "      <td>6.400000</td>\n",
              "      <td>3.712000</td>\n",
              "      <td>1.667710</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>epirubicin</td>\n",
              "      <td>7</td>\n",
              "      <td>20</td>\n",
              "      <td>11200</td>\n",
              "      <td>48</td>\n",
              "      <td>55</td>\n",
              "      <td>5.833333</td>\n",
              "      <td>2.800000</td>\n",
              "      <td>1.375000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>lenvatinib</td>\n",
              "      <td>6</td>\n",
              "      <td>40</td>\n",
              "      <td>11000</td>\n",
              "      <td>50</td>\n",
              "      <td>70</td>\n",
              "      <td>4.285714</td>\n",
              "      <td>2.142857</td>\n",
              "      <td>1.363636</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>carfilzomib hydrochloride</td>\n",
              "      <td>10</td>\n",
              "      <td>20</td>\n",
              "      <td>10700</td>\n",
              "      <td>40</td>\n",
              "      <td>42</td>\n",
              "      <td>8.333333</td>\n",
              "      <td>3.333333</td>\n",
              "      <td>1.308411</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>afinitor</td>\n",
              "      <td>6</td>\n",
              "      <td>35</td>\n",
              "      <td>10000</td>\n",
              "      <td>45</td>\n",
              "      <td>65</td>\n",
              "      <td>4.444444</td>\n",
              "      <td>2.000000</td>\n",
              "      <td>1.300000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>tacrolimus</td>\n",
              "      <td>7</td>\n",
              "      <td>18</td>\n",
              "      <td>9700</td>\n",
              "      <td>45</td>\n",
              "      <td>45</td>\n",
              "      <td>5.932203</td>\n",
              "      <td>2.669492</td>\n",
              "      <td>1.238424</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>votrient</td>\n",
              "      <td>8</td>\n",
              "      <td>18</td>\n",
              "      <td>9000</td>\n",
              "      <td>38</td>\n",
              "      <td>40</td>\n",
              "      <td>6.779661</td>\n",
              "      <td>2.576271</td>\n",
              "      <td>1.145009</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>nivolumab</td>\n",
              "      <td>7</td>\n",
              "      <td>25</td>\n",
              "      <td>10000</td>\n",
              "      <td>42</td>\n",
              "      <td>48</td>\n",
              "      <td>5.600000</td>\n",
              "      <td>2.352000</td>\n",
              "      <td>1.128960</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>carfilzomib</td>\n",
              "      <td>6</td>\n",
              "      <td>16</td>\n",
              "      <td>9300</td>\n",
              "      <td>36</td>\n",
              "      <td>38</td>\n",
              "      <td>5.172414</td>\n",
              "      <td>1.862069</td>\n",
              "      <td>0.760845</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>vandetanib</td>\n",
              "      <td>5</td>\n",
              "      <td>20</td>\n",
              "      <td>10500</td>\n",
              "      <td>35</td>\n",
              "      <td>50</td>\n",
              "      <td>4.166667</td>\n",
              "      <td>1.458333</td>\n",
              "      <td>0.694444</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>cometriq</td>\n",
              "      <td>4</td>\n",
              "      <td>15</td>\n",
              "      <td>9500</td>\n",
              "      <td>40</td>\n",
              "      <td>45</td>\n",
              "      <td>3.478261</td>\n",
              "      <td>1.391304</td>\n",
              "      <td>0.659039</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>hydroxydaunorubicin</td>\n",
              "      <td>5</td>\n",
              "      <td>15</td>\n",
              "      <td>9800</td>\n",
              "      <td>33</td>\n",
              "      <td>35</td>\n",
              "      <td>4.347826</td>\n",
              "      <td>1.434783</td>\n",
              "      <td>0.512422</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>ridaura</td>\n",
              "      <td>5</td>\n",
              "      <td>14</td>\n",
              "      <td>8800</td>\n",
              "      <td>30</td>\n",
              "      <td>30</td>\n",
              "      <td>4.385965</td>\n",
              "      <td>1.315789</td>\n",
              "      <td>0.448565</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>pazopanib</td>\n",
              "      <td>5</td>\n",
              "      <td>12</td>\n",
              "      <td>8000</td>\n",
              "      <td>25</td>\n",
              "      <td>28</td>\n",
              "      <td>4.464286</td>\n",
              "      <td>1.116071</td>\n",
              "      <td>0.390625</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>lyrica</td>\n",
              "      <td>3</td>\n",
              "      <td>12</td>\n",
              "      <td>8500</td>\n",
              "      <td>32</td>\n",
              "      <td>32</td>\n",
              "      <td>2.678571</td>\n",
              "      <td>0.857143</td>\n",
              "      <td>0.322689</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>pregabalin</td>\n",
              "      <td>4</td>\n",
              "      <td>10</td>\n",
              "      <td>9200</td>\n",
              "      <td>28</td>\n",
              "      <td>25</td>\n",
              "      <td>3.636364</td>\n",
              "      <td>1.018182</td>\n",
              "      <td>0.276680</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>cabozantinib</td>\n",
              "      <td>3</td>\n",
              "      <td>10</td>\n",
              "      <td>10000</td>\n",
              "      <td>30</td>\n",
              "      <td>30</td>\n",
              "      <td>2.727273</td>\n",
              "      <td>0.818182</td>\n",
              "      <td>0.245455</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-fe3a49f0-26eb-4dce-a8ad-70398f9034a7')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-fe3a49f0-26eb-4dce-a8ad-70398f9034a7 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-fe3a49f0-26eb-4dce-a8ad-70398f9034a7');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-e05ae26f-beb7-4dd2-adc1-c5610a58aad7\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-e05ae26f-beb7-4dd2-adc1-c5610a58aad7')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-e05ae26f-beb7-4dd2-adc1-c5610a58aad7 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_260d2ff6-0a15-43e2-9d78-1a61298476c7\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_260d2ff6-0a15-43e2-9d78-1a61298476c7 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 28,\n  \"fields\": [\n    {\n      \"column\": \"Drug\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 28,\n        \"samples\": [\n          \"fujimycin\",\n          \"lyrica\",\n          \"caprelsa\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"TAS\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2,\n        \"min\": 3,\n        \"max\": 10,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          9,\n          5,\n          10\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Toxicity\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 8,\n        \"min\": 10,\n        \"max\": 40,\n        \"num_unique_values\": 13,\n        \"samples\": [\n          12,\n          15,\n          20\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"CER ($)\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1800,\n        \"min\": 8000,\n        \"max\": 15000,\n        \"num_unique_values\": 25,\n        \"samples\": [\n          10300,\n          9000,\n          12000\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Biomarker (%)\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 15,\n        \"min\": 25,\n        \"max\": 78,\n        \"num_unique_values\": 24,\n        \"samples\": [\n          52,\n          42,\n          60\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Evidence Score\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 22,\n        \"min\": 25,\n        \"max\": 92,\n        \"num_unique_values\": 23,\n        \"samples\": [\n          48,\n          62,\n          90\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"TAS Adjusted\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1.563862578603667,\n        \"min\": 2.6785714285714284,\n        \"max\": 8.333333333333334,\n        \"num_unique_values\": 26,\n        \"samples\": [\n          6.557377049180328,\n          5.6,\n          8.333333333333334\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Biomarker-Weighted TAS\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1.5068109392254028,\n        \"min\": 0.8181818181818181,\n        \"max\": 5.2734375,\n        \"num_unique_values\": 28,\n        \"samples\": [\n          3.4098360655737707,\n          0.8571428571428571,\n          3.155737704918033\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Final Drug Score\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1.1527844530709241,\n        \"min\": 0.24545454545454543,\n        \"max\": 3.75,\n        \"num_unique_values\": 28,\n        \"samples\": [\n          1.9201018621677541,\n          0.3226890756302521,\n          2.140413399857449\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Calculate PubMed evidence counts\n",
        "pubmed_evidence_counts = df['Drug'].value_counts().reset_index()\n",
        "pubmed_evidence_counts.columns = ['Drug', 'PubMed']\n",
        "\n",
        "# Calculate ArXiv evidence counts\n",
        "arxiv_evidence_counts = arxiv_results['Drug'].value_counts().reset_index()\n",
        "arxiv_evidence_counts.columns = ['Drug', 'ArXiv']\n",
        "\n",
        "# Merge testing results with evidence counts\n",
        "final = df.merge(pubmed_evidence_counts, on=\"Drug\", how=\"left\").fillna(0)\n",
        "final = final.merge(arxiv_evidence_counts, on=\"Drug\", how=\"left\").fillna(0)\n",
        "\n",
        "\n",
        "# Normalize evidence\n",
        "final[\"Evidence Weight\"] = final[\"PubMed\"] * 2 + final[\"ArXiv\"]\n",
        "final[\"Combined Drug Score\"] = (final[\"Final Drug Score\"] * final[\"Evidence Weight\"]).round(2)\n",
        "final.sort_values(by=\"Combined Drug Score\", ascending=False, inplace=True)\n",
        "final[[\"Drug\", \"TAS Adjusted\", \"CER ($)\", \"Biomarker (%)\", \"Evidence Score\", \"PubMed\", \"ArXiv\", \"Combined Drug Score\"]]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 927
        },
        "id": "lNw40LrARq49",
        "outputId": "2fea3168-b0d1-4ce6-d2b4-bf2d9ca2517d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         Drug  TAS Adjusted  CER ($)  Biomarker (%)  \\\n",
              "0                   sorafenib      8.333333    12000             60   \n",
              "1                  everolimus      7.031250    13000             75   \n",
              "2           dopamine agonists      6.666667    12500             78   \n",
              "3                     lenvima      7.200000    13500             70   \n",
              "4                      opdivo      6.923077    12000             68   \n",
              "5                   auranofin      7.031250    11800             68   \n",
              "6                 doxorubicin      7.142857    15000             72   \n",
              "7                     nexavar      6.153846    14000             65   \n",
              "8                    caprelsa      5.737705    11500             55   \n",
              "9                   fujimycin      6.557377    10300             52   \n",
              "10                 ropinirole      4.615385    10800             62   \n",
              "11   epirubicin hydrochloride      6.400000    13800             58   \n",
              "12                 epirubicin      5.833333    11200             48   \n",
              "13                 lenvatinib      4.285714    11000             50   \n",
              "14  carfilzomib hydrochloride      8.333333    10700             40   \n",
              "15                   afinitor      4.444444    10000             45   \n",
              "16                 tacrolimus      5.932203     9700             45   \n",
              "17                   votrient      6.779661     9000             38   \n",
              "18                  nivolumab      5.600000    10000             42   \n",
              "19                carfilzomib      5.172414     9300             36   \n",
              "20                 vandetanib      4.166667    10500             35   \n",
              "21                   cometriq      3.478261     9500             40   \n",
              "22        hydroxydaunorubicin      4.347826     9800             33   \n",
              "23                   ridaura       4.385965     8800             30   \n",
              "24                  pazopanib      4.464286     8000             25   \n",
              "25                     lyrica      2.678571     8500             32   \n",
              "26                 pregabalin      3.636364     9200             28   \n",
              "27               cabozantinib      2.727273    10000             30   \n",
              "\n",
              "    Evidence Score  PubMed  ArXiv  Combined Drug Score  \n",
              "0               90       1    0.0                 7.50  \n",
              "1               92       1    0.0                 7.46  \n",
              "2               88       1    0.0                 7.32  \n",
              "3               88       1    0.0                 6.57  \n",
              "4               80       1    0.0                 6.28  \n",
              "5               75       1    0.0                 6.08  \n",
              "6               85       1    0.0                 5.83  \n",
              "7               85       1    0.0                 4.86  \n",
              "8               78       1    0.0                 4.28  \n",
              "9               58       1    0.0                 3.84  \n",
              "10              70       1    0.0                 3.71  \n",
              "11              62       1    0.0                 3.34  \n",
              "12              55       1    0.0                 2.75  \n",
              "13              70       1    0.0                 2.73  \n",
              "14              42       1    0.0                 2.62  \n",
              "15              65       1    0.0                 2.60  \n",
              "16              45       1    0.0                 2.48  \n",
              "17              40       1    0.0                 2.29  \n",
              "18              48       1    0.0                 2.26  \n",
              "19              38       1    0.0                 1.52  \n",
              "20              50       1    0.0                 1.39  \n",
              "21              45       1    0.0                 1.32  \n",
              "22              35       1    0.0                 1.02  \n",
              "23              30       1    0.0                 0.90  \n",
              "24              28       1    0.0                 0.78  \n",
              "25              32       1    0.0                 0.65  \n",
              "26              25       1    0.0                 0.55  \n",
              "27              30       1    0.0                 0.49  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-760e9df1-a247-4396-949e-2496e09b847f\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Drug</th>\n",
              "      <th>TAS Adjusted</th>\n",
              "      <th>CER ($)</th>\n",
              "      <th>Biomarker (%)</th>\n",
              "      <th>Evidence Score</th>\n",
              "      <th>PubMed</th>\n",
              "      <th>ArXiv</th>\n",
              "      <th>Combined Drug Score</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>sorafenib</td>\n",
              "      <td>8.333333</td>\n",
              "      <td>12000</td>\n",
              "      <td>60</td>\n",
              "      <td>90</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>7.50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>everolimus</td>\n",
              "      <td>7.031250</td>\n",
              "      <td>13000</td>\n",
              "      <td>75</td>\n",
              "      <td>92</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>7.46</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>dopamine agonists</td>\n",
              "      <td>6.666667</td>\n",
              "      <td>12500</td>\n",
              "      <td>78</td>\n",
              "      <td>88</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>7.32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>lenvima</td>\n",
              "      <td>7.200000</td>\n",
              "      <td>13500</td>\n",
              "      <td>70</td>\n",
              "      <td>88</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>6.57</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>opdivo</td>\n",
              "      <td>6.923077</td>\n",
              "      <td>12000</td>\n",
              "      <td>68</td>\n",
              "      <td>80</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>6.28</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>auranofin</td>\n",
              "      <td>7.031250</td>\n",
              "      <td>11800</td>\n",
              "      <td>68</td>\n",
              "      <td>75</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>6.08</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>doxorubicin</td>\n",
              "      <td>7.142857</td>\n",
              "      <td>15000</td>\n",
              "      <td>72</td>\n",
              "      <td>85</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>5.83</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>nexavar</td>\n",
              "      <td>6.153846</td>\n",
              "      <td>14000</td>\n",
              "      <td>65</td>\n",
              "      <td>85</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>4.86</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>caprelsa</td>\n",
              "      <td>5.737705</td>\n",
              "      <td>11500</td>\n",
              "      <td>55</td>\n",
              "      <td>78</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>4.28</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>fujimycin</td>\n",
              "      <td>6.557377</td>\n",
              "      <td>10300</td>\n",
              "      <td>52</td>\n",
              "      <td>58</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>3.84</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>ropinirole</td>\n",
              "      <td>4.615385</td>\n",
              "      <td>10800</td>\n",
              "      <td>62</td>\n",
              "      <td>70</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>3.71</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>epirubicin hydrochloride</td>\n",
              "      <td>6.400000</td>\n",
              "      <td>13800</td>\n",
              "      <td>58</td>\n",
              "      <td>62</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>3.34</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>epirubicin</td>\n",
              "      <td>5.833333</td>\n",
              "      <td>11200</td>\n",
              "      <td>48</td>\n",
              "      <td>55</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>2.75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>lenvatinib</td>\n",
              "      <td>4.285714</td>\n",
              "      <td>11000</td>\n",
              "      <td>50</td>\n",
              "      <td>70</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>2.73</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>carfilzomib hydrochloride</td>\n",
              "      <td>8.333333</td>\n",
              "      <td>10700</td>\n",
              "      <td>40</td>\n",
              "      <td>42</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>2.62</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>afinitor</td>\n",
              "      <td>4.444444</td>\n",
              "      <td>10000</td>\n",
              "      <td>45</td>\n",
              "      <td>65</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>2.60</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>tacrolimus</td>\n",
              "      <td>5.932203</td>\n",
              "      <td>9700</td>\n",
              "      <td>45</td>\n",
              "      <td>45</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>2.48</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>votrient</td>\n",
              "      <td>6.779661</td>\n",
              "      <td>9000</td>\n",
              "      <td>38</td>\n",
              "      <td>40</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>2.29</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>nivolumab</td>\n",
              "      <td>5.600000</td>\n",
              "      <td>10000</td>\n",
              "      <td>42</td>\n",
              "      <td>48</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>2.26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>carfilzomib</td>\n",
              "      <td>5.172414</td>\n",
              "      <td>9300</td>\n",
              "      <td>36</td>\n",
              "      <td>38</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>1.52</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>vandetanib</td>\n",
              "      <td>4.166667</td>\n",
              "      <td>10500</td>\n",
              "      <td>35</td>\n",
              "      <td>50</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>1.39</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>cometriq</td>\n",
              "      <td>3.478261</td>\n",
              "      <td>9500</td>\n",
              "      <td>40</td>\n",
              "      <td>45</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>1.32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>hydroxydaunorubicin</td>\n",
              "      <td>4.347826</td>\n",
              "      <td>9800</td>\n",
              "      <td>33</td>\n",
              "      <td>35</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>1.02</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>ridaura</td>\n",
              "      <td>4.385965</td>\n",
              "      <td>8800</td>\n",
              "      <td>30</td>\n",
              "      <td>30</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>0.90</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>pazopanib</td>\n",
              "      <td>4.464286</td>\n",
              "      <td>8000</td>\n",
              "      <td>25</td>\n",
              "      <td>28</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>0.78</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>lyrica</td>\n",
              "      <td>2.678571</td>\n",
              "      <td>8500</td>\n",
              "      <td>32</td>\n",
              "      <td>32</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>0.65</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>pregabalin</td>\n",
              "      <td>3.636364</td>\n",
              "      <td>9200</td>\n",
              "      <td>28</td>\n",
              "      <td>25</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>0.55</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>cabozantinib</td>\n",
              "      <td>2.727273</td>\n",
              "      <td>10000</td>\n",
              "      <td>30</td>\n",
              "      <td>30</td>\n",
              "      <td>1</td>\n",
              "      <td>0.0</td>\n",
              "      <td>0.49</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-760e9df1-a247-4396-949e-2496e09b847f')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-760e9df1-a247-4396-949e-2496e09b847f button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-760e9df1-a247-4396-949e-2496e09b847f');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-b9105733-05ed-40b0-bced-af082fcbd4bb\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b9105733-05ed-40b0-bced-af082fcbd4bb')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-b9105733-05ed-40b0-bced-af082fcbd4bb button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"final[[\\\"Drug\\\", \\\"TAS Adjusted\\\", \\\"CER ($)\\\", \\\"Biomarker (%)\\\", \\\"Evidence Score\\\", \\\"PubMed\\\", \\\"ArXiv\\\", \\\"Combined Drug Score\\\"]]\",\n  \"rows\": 28,\n  \"fields\": [\n    {\n      \"column\": \"Drug\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 28,\n        \"samples\": [\n          \"fujimycin\",\n          \"lyrica\",\n          \"caprelsa\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"TAS Adjusted\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1.563862578603667,\n        \"min\": 2.6785714285714284,\n        \"max\": 8.333333333333334,\n        \"num_unique_values\": 26,\n        \"samples\": [\n          6.557377049180328,\n          5.6,\n          8.333333333333334\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"CER ($)\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1800,\n        \"min\": 8000,\n        \"max\": 15000,\n        \"num_unique_values\": 25,\n        \"samples\": [\n          10300,\n          9000,\n          12000\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Biomarker (%)\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 15,\n        \"min\": 25,\n        \"max\": 78,\n        \"num_unique_values\": 24,\n        \"samples\": [\n          52,\n          42,\n          60\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Evidence Score\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 22,\n        \"min\": 25,\n        \"max\": 92,\n        \"num_unique_values\": 23,\n        \"samples\": [\n          48,\n          62,\n          90\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"PubMed\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 1,\n        \"max\": 1,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          1\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ArXiv\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.0,\n        \"min\": 0.0,\n        \"max\": 0.0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Combined Drug Score\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2.305447999021118,\n        \"min\": 0.49,\n        \"max\": 7.5,\n        \"num_unique_values\": 28,\n        \"samples\": [\n          3.84\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 13
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "import numpy as np # Used for generating dummy data\n",
        "\n",
        "# Your provided list of drug names\n",
        "drug_names = [\n",
        "    \"sorafenib\",\n",
        "    \"lenvatinib\",\n",
        "    \"cabozantinib\",\n",
        "    \"vandetanib\",\n",
        "    \"everolimus\",\n",
        "    \"pazopanib\",\n",
        "    \"nivolumab\",\n",
        "    \"doxorubicin\",\n",
        "    \"epirubicin\",\n",
        "    \"ropinirole\",\n",
        "    \"pregabalin\",\n",
        "    \"tacrolimus\",\n",
        "    \"auranofin\",\n",
        "    \"carfilzomib\"\n",
        "]\n",
        "\n",
        "# --- Create a DataFrame with your drug names and DUMMY DATA ---\n",
        "# Replace these with your actual \"TAS Adjusted\" and \"CER ($)\" values.\n",
        "# I'm using numpy's random.rand to generate some plausible-looking numbers.\n",
        "num_drugs = len(drug_names)\n",
        "tas_adjusted_data = np.random.uniform(5, 20, num_drugs)  # Random values between 5 and 20 for TAS Adjusted\n",
        "cer_data = np.random.uniform(2000, 15000, num_drugs)    # Random values between 2000 and 15000 for CER ($)\n",
        "\n",
        "df = pd.DataFrame({\n",
        "    \"Drug\": drug_names,\n",
        "    \"TAS Adjusted\": tas_adjusted_data,\n",
        "    \"CER ($)\": cer_data\n",
        "})\n",
        "\n",
        "# --- Plotting Code (as previously explained) ---\n",
        "plt.figure(figsize=(12, 6)) # Increased figure width for more drugs\n",
        "\n",
        "plt.bar(df[\"Drug\"], df[\"TAS Adjusted\"], label=\"TAS Adjusted\", color=\"skyblue\")\n",
        "plt.bar(df[\"Drug\"], df[\"CER ($)\"]/1000, alpha=0.7, label=\"CER ($K)\", color=\"darkblue\") # Changed CER color for contrast\n",
        "\n",
        "plt.ylabel(\"Months / $K\")\n",
        "plt.title(\"TAS Adjusted and Cost per Drug\")\n",
        "plt.legend()\n",
        "plt.xticks(rotation=60, ha='right') # Rotate more and align text to the right for better readability\n",
        "plt.tight_layout()\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 607
        },
        "id": "R7lg2yxZT-lI",
        "outputId": "a8bd8446-936b-4b93-e1fc-d74ea7ca0c37"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1200x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "net = Network(notebook=True, height=\"500px\", width=\"100%\", bgcolor=\"#ffffff\", font_color=\"black\")\n",
        "for node, data in G.nodes(data=True):\n",
        "    net.add_node(node, label=data[\"label\"], title=f\"{data['type']}: {data['label']}\",\n",
        "                 color=\"red\" if data[\"type\"] == \"disease\" else \"blue\")\n",
        "for u, v in G.edges():\n",
        "    net.add_edge(u, v)\n",
        "\n",
        "net.save_graph(\"interactive_graph.html\")\n",
        "IFrame(\"interactive_graph.html\", width=\"100%\", height=\"500px\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 559
        },
        "id": "tWXu780uUbLM",
        "outputId": "cb100e72-9f71-436c-962c-c28e8966e62c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Warning: When  cdn_resources is 'local' jupyter notebook has issues displaying graphics on chrome/safari. Use cdn_resources='in_line' or cdn_resources='remote' if you have issues viewing graphics in a notebook.\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<IPython.lib.display.IFrame at 0x79422e7b29d0>"
            ],
            "text/html": [
              "\n",
              "        <iframe\n",
              "            width=\"100%\"\n",
              "            height=\"500px\"\n",
              "            src=\"interactive_graph.html\"\n",
              "            frameborder=\"0\"\n",
              "            allowfullscreen\n",
              "            \n",
              "        ></iframe>\n",
              "        "
            ]
          },
          "metadata": {},
          "execution_count": 17
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "2514c9d3"
      },
      "source": [
        "import networkx as nx\n",
        "\n",
        "# Create a graph\n",
        "G = nx.Graph()\n",
        "\n",
        "# Add disease node\n",
        "disease = \"anaplastic thyroid cancer\"\n",
        "G.add_node(disease, label=disease, type=\"disease\")\n",
        "\n",
        "# Add drug nodes and edges based on mentions in abstracts\n",
        "# Use the DataFrame from the PubMed search (assuming it's the one with 'Abstract' column)\n",
        "# I'll assume the DataFrame with PubMed results is still available as 'df' from cell s9c_ertvLBCw or dFHMFYFfL-iF\n",
        "# If not, you might need to re-run the PubMed fetching cell or load the data again.\n",
        "pubmed_df = fetch_pubmed_articles(\"(anaplastic thyroid cancer) AND (sorafenib OR lenvatinib OR cabozantinib OR vandetanib OR everolimus OR pazopanib OR nivolumab OR doxorubicin OR epirubicin OR ropinirole OR pregabalin OR tacrolimus OR auranofin OR carfilzomib  )\", max_results=50)\n",
        "\n",
        "for index, row in pubmed_df.iterrows():\n",
        "    # Check if the drug is mentioned in the abstract. Iterate through the drug_list.\n",
        "    abstract = row[\"Abstract\"] if pd.notna(row[\"Abstract\"]) else \"\"\n",
        "    for drug in drug_list:\n",
        "        if drug.lower() in abstract.lower(): # Check if the drug is mentioned in the abstract (case-insensitive)\n",
        "            G.add_node(drug, label=drug, type=\"drug\")\n",
        "            G.add_edge(drug, disease)\n",
        "\n",
        "# You can add more nodes and edges based on other relationships if available in your data\n",
        "\n",
        "# Now you can run the original cell to visualize the graph"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install feedparser\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "w9yGaNbyWNvR",
        "outputId": "48eecc77-f8e4-476e-d366-a09a3eaed3f7"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: feedparser in /usr/local/lib/python3.11/dist-packages (6.0.11)\n",
            "Requirement already satisfied: sgmllib3k in /usr/local/lib/python3.11/dist-packages (from feedparser) (1.0.0)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "from Bio import Entrez\n",
        "import time\n",
        "import feedparser # You might need to install this: pip install feedparser\n",
        "\n",
        "# --- Configuration ---\n",
        "Entrez.email = \"nida.amir0083@gmail.com\" # !!! IMPORTANT: Replace with your actual email\n",
        "# Set a delay to respect API rate limits\n",
        "PUBMED_DELAY = 0.5 # seconds between PubMed requests\n",
        "ARXIV_DELAY = 1.0  # seconds between arXiv requests (can be longer for heavier use)\n",
        "\n",
        "# Your list of drug names\n",
        "drug_names = [\n",
        "    \"sorafenib\",\n",
        "    \"lenvatinib\",\n",
        "    \"cabozantinib\",\n",
        "    \"vandetanib\",\n",
        "    \"everolimus\",\n",
        "    \"pazopanib\",\n",
        "    \"nivolumab\",\n",
        "    \"doxorubicin\",\n",
        "    \"epirubicin\",\n",
        "    \"ropinirole\",\n",
        "    \"pregabalin\",\n",
        "    \"tacrolimus\",\n",
        "    \"auranofin\",\n",
        "    \"carfilzomib\"\n",
        "]\n",
        "\n",
        "enhanced_evidence = []\n",
        "\n",
        "for drug in drug_names:\n",
        "    print(f\"Processing drug: {drug}...\")\n",
        "\n",
        "    # --- PubMed Search and Fetch ---\n",
        "    try:\n",
        "        # Search PubMed for papers related to the drug\n",
        "        handle = Entrez.esearch(db=\"pubmed\", term=f\"{drug} AND (VEGF OR therapeutic OR cancer OR disease)\", retmax=\"20\") # Fetch top 20 results, broadened search term for PubMed too\n",
        "        record = Entrez.read(handle)\n",
        "        pmids = record[\"IdList\"]\n",
        "        handle.close()\n",
        "        time.sleep(PUBMED_DELAY) # Respect rate limits\n",
        "\n",
        "        if pmids:\n",
        "            # Fetch details for each PMID\n",
        "            for pmid in pmids:\n",
        "                try:\n",
        "                    handle_fetch = Entrez.efetch(db=\"pubmed\", id=pmid, retmode=\"xml\")\n",
        "                    pub_record = Entrez.read(handle_fetch)\n",
        "                    handle_fetch.close()\n",
        "                    time.sleep(PUBMED_DELAY) # Respect rate limits\n",
        "\n",
        "                    article = pub_record['PubmedArticle'][0]['MedlineCitation']['Article']\n",
        "                    pubmed_abstract = \"\"\n",
        "                    if 'Abstract' in article and 'AbstractText' in article['Abstract']:\n",
        "                        if isinstance(article['Abstract']['AbstractText'], list):\n",
        "                            pubmed_abstract = \" \".join(str(s) for s in article['Abstract']['AbstractText'])\n",
        "                        else:\n",
        "                            pubmed_abstract = str(article['Abstract']['AbstractText'])\n",
        "                    else:\n",
        "                        pubmed_abstract = \"No abstract available\"\n",
        "\n",
        "                    # Get year\n",
        "                    pubmed_year = \"Unknown\"\n",
        "                    if 'ArticleDate' in article and article['ArticleDate']:\n",
        "                        pubmed_year = article['ArticleDate'][0]['Year']\n",
        "                    elif 'PubDate' in article:\n",
        "                         if 'Year' in article['PubDate']:\n",
        "                             pubmed_year = article['PubDate']['Year']\n",
        "                         elif 'MedlineDate' in article['PubDate']:\n",
        "                             pubmed_year = article['PubDate']['MedlineDate'].split(' ')[0]\n",
        "\n",
        "\n",
        "                    enhanced_evidence.append({\n",
        "                        \"Source\": \"PubMed\",\n",
        "                        \"Drug\": drug,\n",
        "                        \"ID\": pmid,\n",
        "                        \"Year\": pubmed_year,\n",
        "                        \"Key Finding\": pubmed_abstract[:200] + \"...\" if pubmed_abstract != \"No abstract available\" else \"N/A\",\n",
        "                        \"Therapeutic Focus\": \"VEGF\" if \"VEGF\" in pubmed_abstract.upper() else \"Other\",\n",
        "                        \"Evidence Level\": (\"Clinical\" if \"trial\" in pubmed_abstract.lower() else \"Preclinical\"),\n",
        "                        \"Relevance\": min(100, len(pubmed_abstract.split()) // 2)\n",
        "                    })\n",
        "\n",
        "                except Exception as e:\n",
        "                    # print(f\"Error fetching PubMed details for PMID {pmid}: {e}\") # Uncomment for debugging\n",
        "                    enhanced_evidence.append({\n",
        "                        \"Source\": \"PubMed\",\n",
        "                        \"Drug\": drug,\n",
        "                        \"ID\": pmid,\n",
        "                        \"Year\": \"Error\",\n",
        "                        \"Key Finding\": \"Error fetching abstract\",\n",
        "                        \"Therapeutic Focus\": \"Unknown\",\n",
        "                        \"Evidence Level\": \"Unknown\",\n",
        "                        \"Relevance\": 0\n",
        "                    })\n",
        "        else:\n",
        "            print(f\"No PubMed results found for {drug}.\") # This is unlikely for these common drugs\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error searching PubMed for {drug}: {e}\")\n",
        "\n",
        "    # --- arXiv Search and Fetch ---\n",
        "    try:\n",
        "        # Broadened arXiv search query: just the drug name, or drug + very general medical terms\n",
        "        # Choose one of the following:\n",
        "        arxiv_query = f\"all:{drug}\" # Simplest and broadest\n",
        "        # arxiv_query = f\"all:{drug}+AND+(medicine+OR+pharmacology+OR+health)\" # Slightly broader medical context\n",
        "\n",
        "        arxiv_url = f\"http://export.arxiv.org/api/query?search_query={arxiv_query}&start=0&max_results=10\" # Fetch up to 10 results\n",
        "        arxiv_feed = feedparser.parse(arxiv_url)\n",
        "        time.sleep(ARXIV_DELAY) # Respect rate limits\n",
        "\n",
        "        if arxiv_feed.entries:\n",
        "            print(f\"Found {len(arxiv_feed.entries)} arXiv results for {drug}.\")\n",
        "            for entry in arxiv_feed.entries:\n",
        "                arxiv_abstract = entry.summary if hasattr(entry, 'summary') else \"No abstract available\"\n",
        "                arxiv_year = \"Unknown\"\n",
        "                if hasattr(entry, 'published'):\n",
        "                    arxiv_year = entry.published.split('-')[0]\n",
        "\n",
        "                enhanced_evidence.append({\n",
        "                    \"Source\": \"arXiv\",\n",
        "                    \"Drug\": drug,\n",
        "                    \"ID\": entry.id if hasattr(entry, 'id') else \"N/A\",\n",
        "                    \"Year\": arxiv_year,\n",
        "                    \"Key Finding\": arxiv_abstract[:200] + \"...\" if arxiv_abstract != \"No abstract available\" else \"N/A\",\n",
        "                    \"Therapeutic Focus\": \"VEGF\" if \"VEGF\" in arxiv_abstract.upper() else \"Other\",\n",
        "                    \"Evidence Level\": (\"Preprint\" if \"preprint\" in arxiv_abstract.lower() else \"Preclinical\"),\n",
        "                    \"Relevance\": min(100, len(arxiv_abstract.split()) // 2)\n",
        "                })\n",
        "        else:\n",
        "            print(f\"No arXiv results found for {drug}.\")\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error searching arXiv for {drug}: {e}\")\n",
        "\n",
        "\n",
        "# Create DataFrame and sort\n",
        "evidence_df = pd.DataFrame(enhanced_evidence)\n",
        "# Ensure 'Relevance' and 'Year' are numeric for sorting, handle errors\n",
        "evidence_df['Relevance'] = pd.to_numeric(evidence_df['Relevance'], errors='coerce').fillna(0)\n",
        "evidence_df['Year'] = pd.to_numeric(evidence_df['Year'], errors='coerce').fillna(0) # Fill NaN years with 0 for sorting\n",
        "\n",
        "evidence_df = evidence_df.sort_values([\"Relevance\", \"Year\"], ascending=[False, False])\n",
        "\n",
        "print(\"\\n--- Enhanced Evidence DataFrame ---\")\n",
        "print(evidence_df.head(10)) # Print top 10 to see more results\n",
        "print(f\"\\nTotal records fetched: {len(evidence_df)}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3TKPfB_1YROH",
        "outputId": "c7f8b568-cd3a-40b1-a734-b75bcdc663da"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Processing drug: sorafenib...\n",
            "Found 2 arXiv results for sorafenib.\n",
            "Processing drug: lenvatinib...\n",
            "No arXiv results found for lenvatinib.\n",
            "Processing drug: cabozantinib...\n",
            "No arXiv results found for cabozantinib.\n",
            "Processing drug: vandetanib...\n",
            "No arXiv results found for vandetanib.\n",
            "Processing drug: everolimus...\n",
            "Found 1 arXiv results for everolimus.\n",
            "Processing drug: pazopanib...\n",
            "No arXiv results found for pazopanib.\n",
            "Processing drug: nivolumab...\n",
            "No arXiv results found for nivolumab.\n",
            "Processing drug: doxorubicin...\n",
            "Found 10 arXiv results for doxorubicin.\n",
            "Processing drug: epirubicin...\n",
            "Found 1 arXiv results for epirubicin.\n",
            "Processing drug: ropinirole...\n",
            "No arXiv results found for ropinirole.\n",
            "Processing drug: pregabalin...\n",
            "Found 2 arXiv results for pregabalin.\n",
            "Processing drug: tacrolimus...\n",
            "Found 9 arXiv results for tacrolimus.\n",
            "Processing drug: auranofin...\n",
            "No arXiv results found for auranofin.\n",
            "Processing drug: carfilzomib...\n",
            "No arXiv results found for carfilzomib.\n",
            "\n",
            "--- Enhanced Evidence DataFrame ---\n",
            "    Source        Drug        ID    Year  \\\n",
            "1   PubMed   sorafenib  40567390  2025.0   \n",
            "2   PubMed   sorafenib  40562125  2025.0   \n",
            "4   PubMed   sorafenib  40556796  2025.0   \n",
            "6   PubMed   sorafenib  40547009  2025.0   \n",
            "8   PubMed   sorafenib  40542755  2025.0   \n",
            "13  PubMed   sorafenib  40521302  2025.0   \n",
            "14  PubMed   sorafenib  40519720  2025.0   \n",
            "16  PubMed   sorafenib  40518001  2025.0   \n",
            "19  PubMed   sorafenib  40510141  2025.0   \n",
            "22  PubMed  lenvatinib  40568752  2025.0   \n",
            "\n",
            "                                          Key Finding Therapeutic Focus  \\\n",
            "1   Preclinical models have shown that metabolic d...             Other   \n",
            "2   FOXM1 is a critical oncogenic transcription fa...             Other   \n",
            "4   The duration of treatment for desmoid-type fib...             Other   \n",
            "6   Immune checkpoint inhibitors (ICIs) have trans...             Other   \n",
            "8   Hepatocellular carcinoma (HCC) was the third l...             Other   \n",
            "13  <b>Aim:</b> The current in vitro study investi...             Other   \n",
            "14  Osteosarcoma (OS), the most common pediatric b...             Other   \n",
            "16  Sorafenib is a multitargeted tyrosine kinase i...             Other   \n",
            "19  To investigate the effectiveness and safety of...              VEGF   \n",
            "22  With novel RAS-targeted therapies emerging, be...             Other   \n",
            "\n",
            "   Evidence Level  Relevance  \n",
            "1     Preclinical        100  \n",
            "2     Preclinical        100  \n",
            "4        Clinical        100  \n",
            "6     Preclinical        100  \n",
            "8     Preclinical        100  \n",
            "13    Preclinical        100  \n",
            "14    Preclinical        100  \n",
            "16    Preclinical        100  \n",
            "19    Preclinical        100  \n",
            "22    Preclinical        100  \n",
            "\n",
            "Total records fetched: 305\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "\n",
        "# Assume evidence_df is already created.\n",
        "\n",
        "# Calculate total relevance per drug\n",
        "drug_relevance = evidence_df.groupby('Drug')['Relevance'].sum().sort_values(ascending=False)\n",
        "\n",
        "plt.figure(figsize=(12, 7))\n",
        "drug_relevance.plot(kind='bar', color='darkblue') # Using a single color for this aggregated view\n",
        "\n",
        "plt.title(\"Total Relevance Score per Drug\", fontsize=16)\n",
        "plt.xlabel(\"Drug Name\", fontsize=12)\n",
        "plt.ylabel(\"Total Relevance Score\", fontsize=12)\n",
        "plt.xticks(rotation=45, ha='right', fontsize=10) # Rotate drug names for readability\n",
        "plt.yticks(fontsize=10)\n",
        "plt.grid(axis=\"y\", linestyle='--', alpha=0.7)\n",
        "plt.tight_layout()\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 707
        },
        "id": "w_PWyXNAa3lP",
        "outputId": "c8931798-7a6d-4dc3-f8a0-55fcb536ae21"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1200x700 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "\n",
        "# Assume evidence_df is already created.\n",
        "\n",
        "# Pivot table to get relevance for VEGF and Other per drug\n",
        "relevance_pivot = evidence_df.pivot_table(index='Drug', columns='Therapeutic Focus', values='Relevance', aggfunc='sum').fillna(0)\n",
        "\n",
        "# Sort by total relevance (optional, but makes the chart clearer)\n",
        "relevance_pivot['Total'] = relevance_pivot.sum(axis=1)\n",
        "relevance_pivot = relevance_pivot.sort_values(by='Total', ascending=True).drop('Total', axis=1) # Sort ascending for plotting from bottom up\n",
        "\n",
        "plt.figure(figsize=(12, 8))\n",
        "\n",
        "# Define colors for stacking - Added 'Unknown'\n",
        "colors = {\"VEGF\": \"blue\", \"Other\": \"lightblue\", \"Unknown\": \"gray\"}\n",
        "\n",
        "\n",
        "relevance_pivot.plot(kind='barh', stacked=True, color=[colors[col] for col in relevance_pivot.columns], figsize=(12,8))\n",
        "\n",
        "plt.title(\"Relevance Score by Therapeutic Focus per Drug\", fontsize=16)\n",
        "plt.xlabel(\"Relevance Score\", fontsize=12)\n",
        "plt.ylabel(\"Drug Name\", fontsize=12)\n",
        "plt.xticks(fontsize=10)\n",
        "plt.yticks(fontsize=10)\n",
        "plt.grid(axis=\"x\", linestyle='--', alpha=0.7)\n",
        "plt.legend(title=\"Therapeutic Focus\")\n",
        "plt.tight_layout()\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 824
        },
        "id": "Zs7zEvZWbN7Q",
        "outputId": "99620922-a948-4166-a4df-727827129f49"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1200x800 with 0 Axes>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1200x800 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "import seaborn as sns # Good for count plots\n",
        "\n",
        "# Assume evidence_df is already created.\n",
        "\n",
        "plt.figure(figsize=(8, 6))\n",
        "sns.countplot(data=evidence_df, y='Evidence Level', order=evidence_df['Evidence Level'].value_counts().index, palette='viridis')\n",
        "\n",
        "plt.title(\"Distribution of Evidence Levels\", fontsize=16)\n",
        "plt.xlabel(\"Number of Publications\", fontsize=12)\n",
        "plt.ylabel(\"Evidence Level\", fontsize=12)\n",
        "plt.xticks(fontsize=10)\n",
        "plt.yticks(fontsize=10)\n",
        "plt.tight_layout()\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 694
        },
        "id": "LgB6_tcdbh84",
        "outputId": "9c0c8404-6823-46f0-cb84-b283c6fa0de4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-45-391143321.py:8: FutureWarning: \n",
            "\n",
            "Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `y` variable to `hue` and set `legend=False` for the same effect.\n",
            "\n",
            "  sns.countplot(data=evidence_df, y='Evidence Level', order=evidence_df['Evidence Level'].value_counts().index, palette='viridis')\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 800x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "from Bio import Entrez\n",
        "import time\n",
        "# import feedparser # Not strictly needed for this specific output but keep if you're using it for the full data collection\n",
        "\n",
        "# --- Configuration (Make sure Entrez.email is set) ---\n",
        "Entrez.email = \"nida.amir0083@gmail.com\" # !!! IMPORTANT: Replace with your actual email\n",
        "PUBMED_DELAY = 0.5 # seconds between PubMed requests\n",
        "\n",
        "# Assume 'evidence_df' is already populated from your previous code execution.\n",
        "# It should contain 'Source', 'ID', 'Key Finding' (abstract snippet), and 'Year'.\n",
        "\n",
        "clinical_outcomes = []\n",
        "\n",
        "# Filter for PubMed records, as clinical trial details are primarily there\n",
        "pubmed_evidence = evidence_df[evidence_df['Source'] == 'PubMed'].copy()\n",
        "\n",
        "print(\"Extracting detailed clinical outcomes from PubMed records...\")\n",
        "\n",
        "for index, row in pubmed_evidence.iterrows():\n",
        "    pmid = row['ID']\n",
        "    abstract = row['Key Finding'] # This is the truncated abstract from previous step\n",
        "    original_year = row['Year'] # Use the correct column name 'Year'\n",
        "\n",
        "    journal_name = \"Not reported\"\n",
        "    trial_phase = \"Not specified\"\n",
        "    response_rate = \"Not reported\"\n",
        "    pfs = \"Not reported\"\n",
        "\n",
        "    try:\n",
        "        # Re-fetch the full XML to get more details like Journal and fuller abstract\n",
        "        handle = Entrez.efetch(db=\"pubmed\", id=pmid, retmode=\"xml\")\n",
        "        record = Entrez.read(handle)\n",
        "        handle.close()\n",
        "        time.sleep(PUBMED_DELAY) # Respect rate limits\n",
        "\n",
        "        article = record['PubmedArticle'][0]['MedlineCitation']['Article']\n",
        "\n",
        "        # Extract Journal Name\n",
        "        if 'Journal' in article and 'Title' in article['Journal']:\n",
        "            journal_name = article['Journal']['Title']\n",
        "\n",
        "        # Get the full abstract for more reliable keyword searching\n",
        "        full_abstract = \"\"\n",
        "        if 'Abstract' in article and 'AbstractText' in article['Abstract']:\n",
        "            if isinstance(article['Abstract']['AbstractText'], list):\n",
        "                full_abstract = \" \".join(str(s) for s in article['Abstract']['AbstractText'])\n",
        "            else:\n",
        "                full_abstract = str(article['Abstract']['AbstractText'])\n",
        "\n",
        "        # --- VERY BASIC KEYWORD-BASED INFERENCE for clinical outcomes ---\n",
        "        # This is a heuristic and will not be perfectly accurate or extract values.\n",
        "        # For actual value extraction, dedicated NLP tools are required.\n",
        "\n",
        "        abstract_lower = full_abstract.lower()\n",
        "\n",
        "        # Trial Phase\n",
        "        if \"phase i\" in abstract_lower:\n",
        "            trial_phase = \"Phase I\"\n",
        "        elif \"phase ii\" in abstract_lower:\n",
        "            trial_phase = \"Phase II\"\n",
        "        elif \"phase iii\" in abstract_lower:\n",
        "            trial_phase = \"Phase III\"\n",
        "        elif \"phase iv\" in abstract_lower:\n",
        "            trial_phase = \"Phase IV\"\n",
        "        elif \"clinical trial\" in abstract_lower:\n",
        "            trial_phase = \"Clinical Trial (Phase Unknown)\"\n",
        "\n",
        "\n",
        "        # Response Rate (Objective Response Rate, ORR, Complete Response, Partial Response)\n",
        "        if any(term in abstract_lower for term in [\"response rate\", \"orr\", \"objective response\", \"complete response\", \"partial response\", \"cr\", \"pr\"]):\n",
        "            response_rate = \"Reported (see abstract)\" # Placeholder - advanced NLP needed for actual value\n",
        "\n",
        "        # Progression-Free Survival (PFS)\n",
        "        if \"progression-free survival\" in abstract_lower or \"pfs\" in abstract_lower:\n",
        "            pfs = \"Reported (see abstract)\" # Placeholder - advanced NLP needed for actual value\n",
        "\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error fetching/parsing details for PMID {pmid}: {e}\")\n",
        "        # Keep defaults if error occurs\n",
        "\n",
        "    clinical_outcomes.append({\n",
        "        \"Drug\": row['Drug'], # Add Drug column here\n",
        "        \"PMID\": pmid,\n",
        "        \"Trial Phase\": trial_phase,\n",
        "        \"Response Rate\": response_rate,\n",
        "        \"PFS\": pfs,\n",
        "        \"Journal\": journal_name,\n",
        "        \"Year\": original_year\n",
        "    })\n",
        "\n",
        "clinical_outcomes_df = pd.DataFrame(clinical_outcomes)\n",
        "\n",
        "print(\"\\nClinical Outcomes:\")\n",
        "print(clinical_outcomes_df)\n",
        "\n",
        "# You might want to save this to a CSV for easier review\n",
        "# clinical_outcomes_df.to_csv(\"clinical_outcomes.csv\", index=False)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JiWSzDClcgOO",
        "outputId": "35d71db3-3817-46d0-84c9-71793a3b9a26"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Extracting detailed clinical outcomes from PubMed records...\n",
            "Error fetching/parsing details for PMID 20301636: list index out of range\n",
            "Error fetching/parsing details for PMID 37824694: list index out of range\n",
            "\n",
            "Clinical Outcomes:\n",
            "             Drug      PMID    Trial Phase            Response Rate  \\\n",
            "0       sorafenib  40556796  Not specified  Reported (see abstract)   \n",
            "1       sorafenib  40547009  Not specified  Reported (see abstract)   \n",
            "2       sorafenib  40542755  Not specified  Reported (see abstract)   \n",
            "3       sorafenib  40521302  Not specified  Reported (see abstract)   \n",
            "4       sorafenib  40519720  Not specified  Reported (see abstract)   \n",
            "..            ...       ...            ...                      ...   \n",
            "275  cabozantinib  40530149  Not specified             Not reported   \n",
            "276    ropinirole  39231585  Not specified             Not reported   \n",
            "277  cabozantinib  40457830  Not specified             Not reported   \n",
            "278     pazopanib  20301636  Not specified             Not reported   \n",
            "279    ropinirole  37824694  Not specified             Not reported   \n",
            "\n",
            "                         PFS  \\\n",
            "0    Reported (see abstract)   \n",
            "1               Not reported   \n",
            "2    Reported (see abstract)   \n",
            "3               Not reported   \n",
            "4               Not reported   \n",
            "..                       ...   \n",
            "275             Not reported   \n",
            "276             Not reported   \n",
            "277             Not reported   \n",
            "278             Not reported   \n",
            "279             Not reported   \n",
            "\n",
            "                                               Journal    Year  \n",
            "0                                Ecancermedicalscience  2025.0  \n",
            "1                              Frontiers in immunology  2025.0  \n",
            "2    Asian Pacific journal of cancer prevention : A...  2025.0  \n",
            "3            Cancer drug resistance (Alhambra, Calif.)  2025.0  \n",
            "4                             Translational pediatrics  2025.0  \n",
            "..                                                 ...     ...  \n",
            "275                      Translational cancer research  2025.0  \n",
            "276  Journal of neurology, neurosurgery, and psychi...  2025.0  \n",
            "277                                             Cancer     0.0  \n",
            "278                                       Not reported     0.0  \n",
            "279                                       Not reported     0.0  \n",
            "\n",
            "[280 rows x 7 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import re\n",
        "from collections import defaultdict\n",
        "\n",
        "# Assume 'evidence_df' is already populated from your previous data fetching script.\n",
        "# If you are running this code independently, you would need to load it.\n",
        "# Example: evidence_df = pd.read_csv(\"your_combined_evidence_data.csv\")\n",
        "\n",
        "# Ensure 'Key Finding' is a string and handle potential NaNs\n",
        "if 'Key Finding' in evidence_df.columns:\n",
        "    evidence_df['Abstract_Full'] = evidence_df['Key Finding'].fillna('')\n",
        "else:\n",
        "    # Fallback if 'Key Finding' doesn't exist, create a dummy empty column\n",
        "    evidence_df['Abstract_Full'] = ''\n",
        "    print(\"Warning: 'Key Finding' column not found. Abstract-based extractions will be empty.\")\n",
        "\n",
        "\n",
        "# Improved extraction functions (same as yours)\n",
        "def extract_trial_phase(abstract_text):\n",
        "    \"\"\"Enhanced phase detection using the abstract text\"\"\"\n",
        "    text = str(abstract_text).lower() # Already lowercased in the abstract if it came from previous step\n",
        "\n",
        "    # Check for roman numerals first (more reliable)\n",
        "    phase_map = {\n",
        "        'phase i ': 'Phase I',\n",
        "        'phase ii ': 'Phase II',\n",
        "        'phase iii ': 'Phase III',\n",
        "        'phase iv ': 'Phase IV',\n",
        "        'phase 1 ': 'Phase I',\n",
        "        'phase 2 ': 'Phase II',\n",
        "        'phase 3 ': 'Phase III',\n",
        "        'phase 4 ': 'Phase IV' # Added phase 4\n",
        "    }\n",
        "\n",
        "    for term, phase in phase_map.items():\n",
        "        if term in text:\n",
        "            return phase\n",
        "\n",
        "    # Fallback to more flexible matching for Roman numerals with punctuation\n",
        "    if any(x in text for x in ['phase i/', 'phase i)', 'phase i-']):\n",
        "        return 'Phase I'\n",
        "    if any(x in text for x in ['phase ii/', 'phase ii)', 'phase ii-']):\n",
        "        return 'Phase II'\n",
        "    if any(x in text for x in ['phase iii/', 'phase iii)', 'phase iii-']):\n",
        "        return 'Phase III'\n",
        "    if any(x in text for x in ['phase iv/', 'phase iv)', 'phase iv-']):\n",
        "        return 'Phase IV'\n",
        "\n",
        "\n",
        "    # If 'clinical trial' or 'randomized' without specific phase\n",
        "    if any(kw in text for kw in ['clinical trial', 'randomized controlled trial', 'rct', 'prospective study', 'interventional study']):\n",
        "        return 'Clinical Trial (Phase Unknown)'\n",
        "\n",
        "    return 'Phase not specified'\n",
        "\n",
        "def extract_response_data(abstract_text):\n",
        "    \"\"\"Extract both response rate and PFS with more robust patterns\"\"\"\n",
        "    abstract = str(abstract_text)\n",
        "    response_rate = 'Not reported'\n",
        "    pfs = 'Not reported'\n",
        "\n",
        "    # Response rate patterns (ordered by specificity/preference)\n",
        "    rr_patterns = [\n",
        "        r'objective response rate \\(ORR\\):\\s*([\\d\\.]+\\s*%)', # e.g., ORR: 30%\n",
        "        r'ORR.*?([\\d\\.]+\\s*%)', # e.g., ORR was 25%\n",
        "        r'response rate.*?([\\d\\.]+\\s*%)', # e.g., response rate of 40%\n",
        "        r'(\\d+/\\d+)\\s*(responses?|patients? with response)', # e.g., 20/50 responses\n",
        "        r'overall response rate.*?([\\d\\.]+\\s*%)',\n",
        "        r'clinical response rate.*?([\\d\\.]+\\s*%)',\n",
        "    ]\n",
        "\n",
        "    # PFS patterns (ordered by specificity/preference)\n",
        "    pfs_patterns = [\n",
        "        r'median\\s*PFS.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'PFS.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'progression-free survival.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'PFS\\s*of\\s*(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'TTP\\s*of\\s*(\\d+\\.?\\d*)\\s*(months|weeks|days|years)', # Time to progression\n",
        "        r'median\\s*PFS\\s*was\\s*(\\d+\\.?\\d*)', # If no unit specified, assume months\n",
        "    ]\n",
        "\n",
        "    for pattern in rr_patterns:\n",
        "        match = re.search(pattern, abstract, re.IGNORECASE)\n",
        "        if match:\n",
        "            response_rate = match.group(1).strip() # Capture the percentage or fraction\n",
        "            # Standardize percentage format if just a number\n",
        "            if response_rate.isdigit() and '%' not in response_rate:\n",
        "                response_rate += '%'\n",
        "            break\n",
        "\n",
        "    for pattern in pfs_patterns:\n",
        "        match = re.search(pattern, abstract, re.IGNORECASE)\n",
        "        if match:\n",
        "            value = match.group(1).strip()\n",
        "            unit = match.group(2).strip() if len(match.groups()) > 1 and match.group(2) else 'months' # Default to months\n",
        "            pfs = f\"{value} {unit}\"\n",
        "            break\n",
        "\n",
        "    # Check for general mention if no specific value found\n",
        "    if response_rate == 'Not reported' and any(term in abstract.lower() for term in [\"response rate\", \"orr\", \"objective response\"]):\n",
        "        response_rate = \"Mentioned, value not extracted\"\n",
        "    if pfs == 'Not reported' and any(term in abstract.lower() for term in [\"progression-free survival\", \"pfs\", \"time to progression\", \"ttp\"]):\n",
        "        pfs = \"Mentioned, value not extracted\"\n",
        "\n",
        "    return response_rate, pfs\n",
        "\n",
        "\n",
        "# Process clinical trials for ALL drugs\n",
        "clinical_outcomes = []\n",
        "\n",
        "# Filter for PubMed entries, as detailed clinical outcomes are usually found there\n",
        "pubmed_data = evidence_df[evidence_df['Source'] == 'PubMed'].copy()\n",
        "\n",
        "print(\"Processing clinical outcomes for all drugs from PubMed entries...\")\n",
        "\n",
        "for _, row in pubmed_data.iterrows():\n",
        "    # Only process if the record is likely a clinical study\n",
        "    # We look for keywords in the abstract or if Evidence Level is 'Clinical'\n",
        "    is_clinical_study = False\n",
        "    abstract_lower = row['Abstract_Full'].lower()\n",
        "    if 'clinical' in abstract_lower or \\\n",
        "       'trial' in abstract_lower or \\\n",
        "       'randomized' in abstract_lower or \\\n",
        "       'patients' in abstract_lower or \\\n",
        "       ('Evidence Level' in row and row['Evidence Level'] == 'Clinical'): # Check if already classified as clinical\n",
        "        is_clinical_study = True\n",
        "\n",
        "    if is_clinical_study:\n",
        "        response_rate, pfs = extract_response_data(row['Abstract_Full'])\n",
        "        clinical_outcomes.append({\n",
        "            'Drug': row['Drug'], # Add drug name\n",
        "            'PMID': row['ID'],\n",
        "            # We don't have 'Title' in evidence_df, so just use drug name as a placeholder\n",
        "            # If you need Title, you must modify the initial Entrez fetch to include it.\n",
        "            'Trial Phase': extract_trial_phase(row['Abstract_Full']),\n",
        "            'Response Rate': response_rate,\n",
        "            'PFS': pfs,\n",
        "            'Journal': row['Journal'] if 'Journal' in row else 'Not Reported', # Use Journal if available\n",
        "            'Year': row['Year'] # Use the correct column name 'Year'\n",
        "        })\n",
        "\n",
        "# Display results\n",
        "if clinical_outcomes:\n",
        "    print(\"\\nClinical Trial Results Across All Drugs:\")\n",
        "    outcomes_df = pd.DataFrame(clinical_outcomes)\n",
        "    # Sort by Drug, then Year, then Trial Phase for better readability\n",
        "    outcomes_df = outcomes_df.sort_values(by=['Drug', 'Year', 'Trial Phase'], ascending=[True, False, True])\n",
        "    # Select columns as per your sample, including 'Drug'\n",
        "    print(outcomes_df[['Drug', 'PMID', 'Trial Phase', 'Response Rate', 'PFS', 'Journal', 'Year']].to_string(index=False))\n",
        "else:\n",
        "    print(\"No clinical trial data could be extracted from these publications.\")\n",
        "\n",
        "# Additional analysis for papers mentioning specific terms (now applied across all drugs)\n",
        "print(\"\\nKey Papers Analysis (across all drugs):\")\n",
        "# Example terms - adjust as needed\n",
        "analysis_terms = ['combination', 'resistance', 'mutation', 'biomarker', 'pharmacokinetics']\n",
        "\n",
        "for term in analysis_terms:\n",
        "    # Ensure 'Abstract_Full' is used for searching\n",
        "    term_papers = evidence_df[evidence_df['Abstract_Full'].str.contains(term, case=False, na=False)].copy()\n",
        "    print(f\"{len(term_papers)} papers mention '{term}':\")\n",
        "    if not term_papers.empty:\n",
        "        # Include Drug name in the output for these analyses\n",
        "        print(term_papers[['Drug', 'ID', 'Key Finding', 'Source', 'Year']].head(3).to_string(index=False)) # Show top 3 abstracts\n",
        "    print()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pgo8_ztgfxkC",
        "outputId": "a8b06617-dd55-4122-f22d-8047873c8a4c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Processing clinical outcomes for all drugs from PubMed entries...\n",
            "\n",
            "Clinical Trial Results Across All Drugs:\n",
            "        Drug     PMID                    Trial Phase                  Response Rate          PFS      Journal   Year\n",
            "   auranofin 40360957            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   auranofin 40333653            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   auranofin 40264668            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   auranofin 40393152            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   auranofin 40371988            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "cabozantinib 40526090            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "cabozantinib 40523369            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "cabozantinib 40502628            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "cabozantinib 40457584            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "cabozantinib 40446543            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "cabozantinib 40533744            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "cabozantinib 40439196            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "cabozantinib 40549043            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            " carfilzomib 40447540 Clinical Trial (Phase Unknown)                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40380262 Clinical Trial (Phase Unknown)                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40397818                        Phase I                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40485906                       Phase II                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40459097            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40432724            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40422527            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40354013            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40302641            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40389585            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40516200            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40356496            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " carfilzomib 40493473            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            " doxorubicin 40551015            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " doxorubicin 40558642            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            " doxorubicin 40552131            Phase not specified                   Not reported Not reported Not Reported 2024.0\n",
            "  epirubicin 40422528            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  epirubicin 40414961            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  epirubicin 40405962            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  epirubicin 40405281            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  epirubicin 40388071            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  epirubicin 40381849            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  epirubicin 40366635            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  epirubicin 40550018            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  epirubicin 40392219            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  everolimus 40533705 Clinical Trial (Phase Unknown)                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40468525 Clinical Trial (Phase Unknown)                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40458731                       Phase II                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40539509            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40522307            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40506517            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40479621            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40464674            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40463869            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  everolimus 40503855            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  lenvatinib 40556750                      Phase III                   Not reported Not reported Not Reported 2025.0\n",
            "  lenvatinib 40535653            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  lenvatinib 40534866            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  lenvatinib 40517686            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  lenvatinib 40550161            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "   nivolumab 40557547            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40550568            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40547025            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40543743            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40532471            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40528805            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40547858            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40549116            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   nivolumab 40552104            Phase not specified Mentioned, value not extracted Not reported Not Reported 2025.0\n",
            "   nivolumab 40526078                       Phase II                   Not reported Not reported Not Reported    0.0\n",
            "   nivolumab 40552731            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "   nivolumab 40549043            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "   nivolumab 40534172            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "   pazopanib 40457584            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   pazopanib 40450699            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   pazopanib 40392078            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   pazopanib 40285941            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   pazopanib 40263237            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   pazopanib 40479637            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   pazopanib 40344484            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "   pazopanib 40296413            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  pregabalin 40543266            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  pregabalin 40504234            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  pregabalin 40458461            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  pregabalin 40458269            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  pregabalin 40536375            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  pregabalin 40418104            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  ropinirole 40065414 Clinical Trial (Phase Unknown)                   Not reported Not reported Not Reported 2025.0\n",
            "  ropinirole 40254926            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  ropinirole 40248871            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  ropinirole 40055961            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  ropinirole 39812843            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  ropinirole 39212742            Phase not specified                   Not reported Not reported Not Reported 2024.0\n",
            "  ropinirole 39199470            Phase not specified                   Not reported Not reported Not Reported 2024.0\n",
            "  ropinirole 39160111            Phase not specified                   Not reported Not reported Not Reported 2024.0\n",
            "  ropinirole 39324694            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "   sorafenib 40528356                       Phase II Mentioned, value not extracted Not reported Not Reported 2025.0\n",
            "   sorafenib 40556796            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   sorafenib 40502851            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   sorafenib 40518650            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   sorafenib 40533744            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "   sorafenib 40538514            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  tacrolimus 40554429 Clinical Trial (Phase Unknown)                   Not reported Not reported Not Reported 2025.0\n",
            "  tacrolimus 40557335            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  tacrolimus 40545390            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  tacrolimus 40531551            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  tacrolimus 40550729            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  tacrolimus 40527803            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "  vandetanib 40406949            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  vandetanib 40297138            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  vandetanib 40022869            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  vandetanib 39987774            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  vandetanib 39637954            Phase not specified                   Not reported Not reported Not Reported 2025.0\n",
            "  vandetanib 39767829            Phase not specified                   Not reported Not reported Not Reported 2024.0\n",
            "  vandetanib 39692930            Phase not specified                   Not reported Not reported Not Reported 2024.0\n",
            "  vandetanib 39643203            Phase not specified                   Not reported Not reported Not Reported 2024.0\n",
            "  vandetanib 40102263            Phase not specified                   Not reported Not reported Not Reported    0.0\n",
            "\n",
            "Key Papers Analysis (across all drugs):\n",
            "12 papers mention 'combination':\n",
            "        Drug       ID                                                                                                                                                                                                 Key Finding Source   Year\n",
            "  lenvatinib 40538375 This study includes a novel chemo-herbal combination using biochanin A (BCA) and lenvatinib (LTB) to synergize each other's anti-cancer activities. Phenylboronic acid (PBA)-functionalized poly (lactic... PubMed 2025.0\n",
            "cabozantinib 40423789 The optimal first-line therapy for metastatic renal cell carcinoma (mRCC) remains uncertain, despite recent advancements in immune-based combinations. This retrospective study compares the effectivene... PubMed 2025.0\n",
            " doxorubicin 40558513 A myriad of biological effects can be stimulated by ultrasound (US) for the treatment of cancer. The objective of our research was to investigate the effect of ultrasound alone and in combination with... PubMed 2025.0\n",
            "\n",
            "14 papers mention 'resistance':\n",
            "        Drug       ID                                                                                                                                                                                                 Key Finding Source   Year\n",
            "   sorafenib 40521302 <b>Aim:</b> The current in vitro study investigated the role of Period 2 (PER2) in aggressiveness and the acquisition of drug resistance in hepatocellular carcinoma (HCC). <b>Methods:</b> Parental PLC... PubMed 2025.0\n",
            "  lenvatinib 40517686 Lenvatinib resistance (LR) profoundly exacerbates the prognosis of patients afflicted with advanced hepatocellular carcinoma (HCC). As pivotal mediators of intercellular communication, exosomes have b... PubMed 2025.0\n",
            "cabozantinib 40446543 Ovarian cancer remains the third most prevalent and deadliest gynecologic malignancy worldwide, with most patients eventually developing resistance to platinum-based chemotherapy. This highlights a cr... PubMed 2025.0\n",
            "\n",
            "5 papers mention 'mutation':\n",
            "        Drug       ID                                                                                                                                                                                                 Key Finding Source   Year\n",
            "  everolimus 40539509 Increasing numbers of clinical cohorts have detected CCND2 mutations in acute myeloid leukemia, especially in the subtype of acute myeloid leukemia with the t(8;21) translocation. This acute myeloid l... PubMed 2025.0\n",
            "  vandetanib 39716145 Medullary Thyroid Carcinoma (MTC) is closely associated with mutations in the RET proto-oncogene, placing the activated RET protein at the center of MTC pathogenesis. Existing therapeutic solutions, p... PubMed 2024.0\n",
            "cabozantinib 40437874 Mutations in c-MET receptor tyrosine kinase (MET) can be primary oncogenic drivers of multiple tumour types or can be acquired as mechanisms of resistance to therapy. MET tyrosine kinase inhibitors (T... PubMed    0.0\n",
            "\n",
            "3 papers mention 'biomarker':\n",
            "       Drug       ID                                                                                                                                                                                                 Key Finding Source   Year\n",
            "  sorafenib 40519720 Osteosarcoma (OS), the most common pediatric bone tumor, faces challenges with frequent relapse despite treatment advances. Identifying early diagnostic biomarkers and therapeutic targets is critical.... PubMed 2025.0\n",
            " epirubicin 40409440 Non-muscle-invasive bladder cancer (NMIBC) is highly heterogeneous, with frequent recurrence and progression. Identifying biomarkers can improve the prediction of therapeutic response and prognosis, g... PubMed 2025.0\n",
            "doxorubicin 40551015 Chemotherapies are often given without precision biomarkers, exposing patients to toxic side effects without guaranteed benefit. Here we present chromosomal instability signature biomarkers that ident... PubMed 2025.0\n",
            "\n",
            "4 papers mention 'pharmacokinetics':\n",
            "        Drug                                ID                                                                                                                                                                                                   Key Finding Source   Year\n",
            "cabozantinib                          40541594   This study investigated whether the \"RT-PK\" phenomenon, referring to radiation therapy's effects on the pharmacokinetics of chemotherapeutic agents, occurs with cabozantinib, a multikinase inhibitor, ... PubMed 2025.0\n",
            "   pazopanib                          40450699   Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics... PubMed 2025.0\n",
            "  tacrolimus http://arxiv.org/abs/2304.05738v1 Background: Various population pharmacokinetic models have been developed to\\ndescribe the pharmacokinetics of tacrolimus in adult liver transplantation.\\nHowever, their extrapolated predictive performa...  arXiv 2023.0\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import re\n",
        "from collections import defaultdict\n",
        "\n",
        "# Manual results for known trials (curate these first)\n",
        "# IMPORTANT: Ensure PMIDs here are strings to match the 'ID' column in evidence_df\n",
        "MANUAL_RESULTS = {\n",
        "    '36681089': {  # NRG/RTOG 0912 trial (Example Pazopanib)\n",
        "        'Trial Phase': 'Phase II',\n",
        "        'Response Rate': '35% (pazopanib arm)',\n",
        "        'PFS': '5.6 months (pazopanib arm)',\n",
        "        'OS': '6.3 months (pazopanib arm)',\n",
        "        'Notes': 'From published results in Lancet Oncology'\n",
        "    },\n",
        "    '22774206': {  # Another known trial (Example Pazopanib)\n",
        "        'Trial Phase': 'Phase II',\n",
        "        'Response Rate': '20%',\n",
        "        'PFS': '3.1 months',\n",
        "        'OS': 'Not reported',\n",
        "        'Notes': 'Single-arm study'\n",
        "    },\n",
        "    # Add more manual results for other drugs/PMIDs as you identify them\n",
        "    # Example for Sorafenib (dummy PMID and values)\n",
        "    '30000000': {\n",
        "        'Trial Phase': 'Phase III',\n",
        "        'Response Rate': '15%',\n",
        "        'PFS': '4.5 months',\n",
        "        'OS': '10.7 months',\n",
        "        'Notes': 'Sorafenib trial example'\n",
        "    },\n",
        "    '30000001': {\n",
        "        'Trial Phase': 'Phase I',\n",
        "        'Response Rate': 'Not reported',\n",
        "        'PFS': 'Not reached',\n",
        "        'OS': 'Not reached',\n",
        "        'Notes': 'Sorafenib Phase I example'\n",
        "    }\n",
        "}\n",
        "\n",
        "# --- Automated extraction functions (copied from your previous working code) ---\n",
        "def extract_trial_phase(abstract_text):\n",
        "    \"\"\"Enhanced phase detection using the abstract text\"\"\"\n",
        "    text = str(abstract_text).lower()\n",
        "\n",
        "    phase_map = {\n",
        "        'phase i ': 'Phase I', 'phase ii ': 'Phase II', 'phase iii ': 'Phase III', 'phase iv ': 'Phase IV',\n",
        "        'phase 1 ': 'Phase I', 'phase 2 ': 'Phase II', 'phase 3 ': 'Phase III', 'phase 4 ': 'Phase IV'\n",
        "    }\n",
        "    for term, phase in phase_map.items():\n",
        "        if term in text:\n",
        "            return phase\n",
        "\n",
        "    if any(x in text for x in ['phase i/', 'phase i)', 'phase i-']): return 'Phase I'\n",
        "    if any(x in text for x in ['phase ii/', 'phase ii)', 'phase ii-']): return 'Phase II'\n",
        "    if any(x in text for x in ['phase iii/', 'phase iii)', 'phase iii-']): return 'Phase III'\n",
        "    if any(x in text for x in ['phase iv/', 'phase iv)', 'phase iv-']): return 'Phase IV'\n",
        "\n",
        "    if any(kw in text for kw in ['clinical trial', 'randomized controlled trial', 'rct', 'prospective study', 'interventional study']):\n",
        "        return 'Clinical Trial (Phase Unknown)'\n",
        "    return 'Phase not specified'\n",
        "\n",
        "def extract_response_data(abstract_text):\n",
        "    \"\"\"Extract both response rate and PFS with more robust patterns, and add OS\"\"\"\n",
        "    abstract = str(abstract_text)\n",
        "    response_rate = 'Not reported'\n",
        "    pfs = 'Not reported'\n",
        "    os = 'Not reported' # Added OS\n",
        "\n",
        "    rr_patterns = [\n",
        "        r'objective response rate \\(ORR\\):\\s*([\\d\\.]+\\s*%)', r'ORR.*?([\\d\\.]+\\s*%)',\n",
        "        r'response rate.*?([\\d\\.]+\\s*%)', r'(\\d+/\\d+)\\s*(responses?|patients? with response)',\n",
        "        r'overall response rate.*?([\\d\\.]+\\s*%)', r'clinical response rate.*?([\\d\\.]+\\s*%)',\n",
        "    ]\n",
        "    pfs_patterns = [\n",
        "        r'median\\s*PFS.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)', r'PFS.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'progression-free survival.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'PFS\\s*of\\s*(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'TTP\\s*of\\s*(\\d+\\.?\\d*)\\s*(months|weeks|days|years)', r'median\\s*PFS\\s*was\\s*(\\d+\\.?\\d*)',\n",
        "    ]\n",
        "    os_patterns = [ # Added OS patterns\n",
        "        r'median\\s*OS.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)', r'OS.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'overall survival.*?(\\d+\\.?\\d*)\\s*(months|weeks|days|years)',\n",
        "        r'OS\\s*of\\s*(\\d+\\.?\\d*)\\s*(months|weeks|days|years)', r'median\\s*OS\\s*was\\s*(\\d+\\.?\\d*)',\n",
        "    ]\n",
        "\n",
        "\n",
        "    for pattern in rr_patterns:\n",
        "        match = re.search(pattern, abstract, re.IGNORECASE)\n",
        "        if match:\n",
        "            response_rate = match.group(1).strip()\n",
        "            if response_rate.isdigit() and '%' not in response_rate:\n",
        "                response_rate += '%'\n",
        "            break\n",
        "    for pattern in pfs_patterns:\n",
        "        match = re.search(pattern, abstract, re.IGNORECASE)\n",
        "        if match:\n",
        "            value = match.group(1).strip()\n",
        "            unit = match.group(2).strip() if len(match.groups()) > 1 and match.group(2) else 'months'\n",
        "            pfs = f\"{value} {unit}\"\n",
        "            break\n",
        "    for pattern in os_patterns: # Apply OS patterns\n",
        "        match = re.search(pattern, abstract, re.IGNORECASE)\n",
        "        if match:\n",
        "            value = match.group(1).strip()\n",
        "            unit = match.group(2).strip() if len(match.groups()) > 1 and match.group(2) else 'months'\n",
        "            os = f\"{value} {unit}\"\n",
        "            break\n",
        "\n",
        "    if response_rate == 'Not reported' and any(term in abstract.lower() for term in [\"response rate\", \"orr\", \"objective response\"]):\n",
        "        response_rate = \"Mentioned, value not extracted\"\n",
        "    if pfs == 'Not reported' and any(term in abstract.lower() for term in [\"progression-free survival\", \"pfs\", \"time to progression\", \"ttp\"]):\n",
        "        pfs = \"Mentioned, value not extracted\"\n",
        "    if os == 'Not reported' and any(term in abstract.lower() for term in [\"overall survival\", \"os\"]): # Mentioned OS\n",
        "        os = \"Mentioned, value not extracted\"\n",
        "\n",
        "    return response_rate, pfs, os # Return OS\n",
        "\n",
        "# --- Modified get_trial_results to integrate automated extraction ---\n",
        "def get_trial_results(pmid, abstract_text):\n",
        "    \"\"\"\n",
        "    Get results with manual override for known trials.\n",
        "    Falls back to automated extraction for clinical trials not manually specified.\n",
        "    \"\"\"\n",
        "    # Check manual results first\n",
        "    if str(pmid) in MANUAL_RESULTS:\n",
        "        return MANUAL_RESULTS[str(pmid)]\n",
        "\n",
        "    # Fallback to automated extraction only for records identified as clinical trials\n",
        "    abstract_lower = str(abstract_text).lower()\n",
        "    if 'clinical' in abstract_lower or 'trial' in abstract_lower or \\\n",
        "       'randomized' in abstract_lower or 'patients' in abstract_lower:\n",
        "\n",
        "        phase = extract_trial_phase(abstract_text)\n",
        "        response_rate, pfs, os_val = extract_response_data(abstract_text) # Get OS here\n",
        "\n",
        "        return {\n",
        "            'Trial Phase': phase,\n",
        "            'Response Rate': response_rate,\n",
        "            'PFS': pfs,\n",
        "            'OS': os_val # Include OS\n",
        "        }\n",
        "\n",
        "    # If not a manually defined trial and not identified as a clinical study by keywords\n",
        "    return {\n",
        "        'Trial Phase': 'Not a clinical trial',\n",
        "        'Response Rate': 'Not reported',\n",
        "        'PFS': 'Not reported',\n",
        "        'OS': 'Not reported'\n",
        "    }\n",
        "\n",
        "# --- Load your data (assuming evidence_df is available from previous steps) ---\n",
        "# If running this code standalone, uncomment and load your combined evidence data\n",
        "# evidence_df = pd.read_csv(\"your_combined_evidence_data.csv\")\n",
        "\n",
        "# Ensure necessary columns are present and handled\n",
        "if 'Key Finding' not in evidence_df.columns:\n",
        "    evidence_df['Key Finding'] = '' # Create if missing\n",
        "if 'Journal' not in evidence_df.columns:\n",
        "    evidence_df['Journal'] = 'Not Reported' # Create if missing\n",
        "if 'Year_Str' not in evidence_df.columns:\n",
        "    # Ensure Year_Str is created if it's not already from previous steps\n",
        "    evidence_df['Year_Str'] = evidence_df['Year'].apply(lambda x: str(int(x)) if pd.notna(x) and pd.api.types.is_numeric_dtype(type(x)) else str(x)).str.replace(r'\\.0$', '', regex=True)\n",
        "\n",
        "\n",
        "# Process all relevant papers (only PubMed for clinical trial details)\n",
        "clinical_outcomes = []\n",
        "pubmed_data = evidence_df[evidence_df['Source'] == 'PubMed'].copy()\n",
        "\n",
        "print(\"Processing clinical outcomes for all drugs from PubMed entries...\")\n",
        "\n",
        "for _, row in pubmed_data.iterrows():\n",
        "    # Pass 'ID' (PMID) and 'Key Finding' (Abstract) to the function\n",
        "    results = get_trial_results(row['ID'], row['Key Finding'])\n",
        "\n",
        "    # Only append if it's considered a clinical trial (either manual or auto-extracted)\n",
        "    # This prevents adding 'Not a clinical trial' entries to the clinical_outcomes list\n",
        "    if results['Trial Phase'] != 'Not a clinical trial':\n",
        "        clinical_outcomes.append({\n",
        "            'Drug': row['Drug'],\n",
        "            'PMID': row['ID'],\n",
        "            'Title': row.get('Title', 'No Title Available')[:60] + '...' if len(str(row.get('Title', 'No Title Available'))) > 60 else row.get('Title', 'No Title Available'), # Get title if available\n",
        "            **results, # Unpack the dictionary of results\n",
        "            'Journal': row['Journal'],\n",
        "            'Year': row['Year_Str']\n",
        "        })\n",
        "\n",
        "# Create and display results\n",
        "if clinical_outcomes:\n",
        "    print(\"\\nClinical Trial Results Across All Drugs:\")\n",
        "    outcomes_df = pd.DataFrame(clinical_outcomes)\n",
        "    # Sort for better readability\n",
        "    outcomes_df = outcomes_df.sort_values(by=['Drug', 'Year', 'Trial Phase'], ascending=[True, False, True])\n",
        "    print(outcomes_df[['Drug', 'PMID', 'Trial Phase', 'Response Rate', 'PFS', 'OS', 'Journal', 'Year']].to_string(index=False))\n",
        "else:\n",
        "    print(\"No clinical trial data could be extracted or identified.\")\n",
        "\n",
        "# Generate key findings (now across all drugs)\n",
        "print(\"\\nKey Findings (across all drugs):\")\n",
        "\n",
        "if clinical_outcomes: # Check if there are any clinical outcomes to analyze\n",
        "    # Convert 'Year' to numeric for sorting/grouping, coercing errors\n",
        "    outcomes_df['Year_Numeric'] = pd.to_numeric(outcomes_df['Year'], errors='coerce')\n",
        "\n",
        "    # Count trials by phase\n",
        "    phase_counts = outcomes_df['Trial Phase'].value_counts()\n",
        "    print(\"Trial Phases Distribution:\")\n",
        "    print(phase_counts.to_string())\n",
        "    print()\n",
        "\n",
        "    # Identify drugs with highest reported relevance (assuming you want to use the 'Relevance' from evidence_df)\n",
        "    # This might require merging or referencing back to the original evidence_df\n",
        "    # For now, let's just find drugs with the most identified clinical trials\n",
        "    drug_trial_counts = outcomes_df['Drug'].value_counts()\n",
        "    print(\"Drugs with Most Identified Clinical Trials:\")\n",
        "    print(drug_trial_counts.head(5).to_string()) # Top 5 drugs\n",
        "    print()\n",
        "\n",
        "    # Example: Phase II trials across all drugs\n",
        "    phase_ii_all_drugs = outcomes_df[outcomes_df['Trial Phase'].str.contains('Phase II', case=False, na=False)]\n",
        "    print(f\"- {len(phase_ii_all_drugs)} Phase II trials identified across all drugs\")\n",
        "\n",
        "    if not phase_ii_all_drugs.empty:\n",
        "        print(\"\\nTop 5 Phase II Trial Details (by year, most recent first):\")\n",
        "        # Sort by Year, then Response Rate (if available, requires more parsing)\n",
        "        print(phase_ii_all_drugs.sort_values(by='Year_Numeric', ascending=False).head(5)[\n",
        "            ['Drug', 'PMID', 'Response Rate', 'PFS', 'OS', 'Journal', 'Year']\n",
        "        ].to_string(index=False))\n",
        "    print()\n",
        "else:\n",
        "    print(\"No clinical trial data available for further analysis.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Led0iiMfgukc",
        "outputId": "15d99e11-f279-40d1-cede-13dc349390ed"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Processing clinical outcomes for all drugs from PubMed entries...\n",
            "\n",
            "Clinical Trial Results Across All Drugs:\n",
            "        Drug     PMID                    Trial Phase                  Response Rate          PFS                             OS      Journal Year\n",
            "   auranofin 40360957            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "   auranofin 40333653            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "   auranofin 40393152            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "   auranofin 40371988            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "cabozantinib 40523369            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "cabozantinib 40446543            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "cabozantinib 40549043            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            " carfilzomib 40447540 Clinical Trial (Phase Unknown)                   Not reported Not reported                   Not reported Not Reported 2025\n",
            " carfilzomib 40380262 Clinical Trial (Phase Unknown)                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            " carfilzomib 40397818                        Phase I                   Not reported Not reported                   Not reported Not Reported 2025\n",
            " carfilzomib 40485906                       Phase II                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            " carfilzomib 40459097            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            " carfilzomib 40432724            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            " carfilzomib 40302641            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            " carfilzomib 40389585            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            " carfilzomib 40516200            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            " carfilzomib 40356496            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            " carfilzomib 40493473            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported    0\n",
            " doxorubicin 40551015            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            " doxorubicin 40558642            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  epirubicin 40422528            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  epirubicin 40414961            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  epirubicin 40388071            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  epirubicin 40366635            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  epirubicin 40550018            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported    0\n",
            "  everolimus 40533705 Clinical Trial (Phase Unknown)                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  everolimus 40468525 Clinical Trial (Phase Unknown)                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  everolimus 40458731                       Phase II                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  everolimus 40539509            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  everolimus 40522307            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  lenvatinib 40556750                      Phase III                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  lenvatinib 40535653            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  lenvatinib 40534866            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  lenvatinib 40517686            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  lenvatinib 40550161            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "   nivolumab 40532471            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "   nivolumab 40528805            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "   nivolumab 40547858            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "   nivolumab 40526078                       Phase II                   Not reported Not reported Mentioned, value not extracted Not Reported    0\n",
            "   nivolumab 40549043            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "   nivolumab 40534172            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "   pazopanib 40450699            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "   pazopanib 40392078            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "   pazopanib 40285941            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "   pazopanib 40263237            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "   pazopanib 40344484            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "  pregabalin 40543266            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  pregabalin 40458461            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  pregabalin 40458269            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  ropinirole 40065414 Clinical Trial (Phase Unknown)                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  ropinirole 39812843            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  ropinirole 39212742            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2024\n",
            "  ropinirole 39160111            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2024\n",
            "  ropinirole 39324694            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "   sorafenib 40528356                       Phase II Mentioned, value not extracted Not reported                   Not reported Not Reported 2025\n",
            "   sorafenib 40556796            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "   sorafenib 40502851            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "   sorafenib 40538514            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "  tacrolimus 40554429 Clinical Trial (Phase Unknown)                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  tacrolimus 40557335            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  tacrolimus 40545390            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            "  tacrolimus 40550729            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported    0\n",
            "  tacrolimus 40527803            Phase not specified                   Not reported Not reported Mentioned, value not extracted Not Reported    0\n",
            "  vandetanib 39643203            Phase not specified                   Not reported Not reported                   Not reported Not Reported 2024\n",
            "  vandetanib 40102263            Phase not specified                   Not reported Not reported                   Not reported Not Reported    0\n",
            "\n",
            "Key Findings (across all drugs):\n",
            "Trial Phases Distribution:\n",
            "Trial Phase\n",
            "Phase not specified               53\n",
            "Clinical Trial (Phase Unknown)     6\n",
            "Phase II                           4\n",
            "Phase I                            1\n",
            "Phase III                          1\n",
            "\n",
            "Drugs with Most Identified Clinical Trials:\n",
            "Drug\n",
            "carfilzomib    11\n",
            "nivolumab       6\n",
            "everolimus      5\n",
            "pazopanib       5\n",
            "lenvatinib      5\n",
            "\n",
            "- 5 Phase II trials identified across all drugs\n",
            "\n",
            "Top 5 Phase II Trial Details (by year, most recent first):\n",
            "       Drug     PMID                  Response Rate          PFS                             OS      Journal Year\n",
            "carfilzomib 40485906                   Not reported Not reported Mentioned, value not extracted Not Reported 2025\n",
            " everolimus 40458731                   Not reported Not reported                   Not reported Not Reported 2025\n",
            " lenvatinib 40556750                   Not reported Not reported                   Not reported Not Reported 2025\n",
            "  sorafenib 40528356 Mentioned, value not extracted Not reported                   Not reported Not Reported 2025\n",
            "  nivolumab 40526078                   Not reported Not reported Mentioned, value not extracted Not Reported    0\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "import re\n",
        "from statsmodels.stats.power import tt_ind_solve_power\n",
        "\n",
        "# Assuming 'clinical_outcomes_df' is available from the previous script's execution.\n",
        "# If not, you'd load it here (e.g., outcomes_df = pd.read_csv(\"clinical_outcomes.csv\"))\n",
        "\n",
        "# Define a generalized historical PFS baseline\n",
        "# This value might need to be adjusted based on the specific context of your analysis\n",
        "# e.g., median PFS for standard of care in a broad cancer type, or placebo arm in trials.\n",
        "# For simplicity, we'll use a placeholder.\n",
        "GENERAL_HISTORICAL_PFS_BASELINE = 3.0 # months (e.g., typical PFS for standard of care in a given cancer setting)\n",
        "\n",
        "print(f\"Using a general historical PFS baseline of {GENERAL_HISTORICAL_PFS_BASELINE} months for comparison.\")\n",
        "\n",
        "# --- Helper function to parse PFS strings into numeric values (in months) ---\n",
        "def parse_pfs_to_months(pfs_str):\n",
        "    if not isinstance(pfs_str, str):\n",
        "        return np.nan\n",
        "    pfs_lower = pfs_str.lower()\n",
        "\n",
        "    # Prioritize values that were actually extracted (not just \"Mentioned, value not extracted\")\n",
        "    if \"not reported\" in pfs_lower or \"not reached\" in pfs_lower or \"mentioned, value not extracted\" in pfs_lower:\n",
        "        return np.nan\n",
        "\n",
        "    match = re.search(r'(\\d+\\.?\\d*)\\s*(months|weeks|days|years)', pfs_lower)\n",
        "    if match:\n",
        "        value = float(match.group(1))\n",
        "        unit = match.group(2)\n",
        "        if unit == 'weeks':\n",
        "            return value / 4.345 # Approximate weeks to months\n",
        "        elif unit == 'days':\n",
        "            return value / 30.417 # Approximate days to months\n",
        "        elif unit == 'years':\n",
        "            return value * 12\n",
        "        else: # months\n",
        "            return value\n",
        "\n",
        "    # Fallback for numbers without explicit units if they look like months (e.g., \"5.6\")\n",
        "    try:\n",
        "        if re.match(r'^\\d+\\.?\\d*$', pfs_str.strip()):\n",
        "            return float(pfs_str.strip())\n",
        "    except ValueError:\n",
        "        pass\n",
        "\n",
        "    return np.nan # Return NaN if parsing fails\n",
        "\n",
        "# Apply the parsing function to the PFS column\n",
        "clinical_outcomes_df['PFS_Numeric'] = clinical_outcomes_df['PFS'].apply(parse_pfs_to_months)\n",
        "\n",
        "# --- Calculate effect sizes and sample sizes for each drug ---\n",
        "drug_analysis_results = []\n",
        "\n",
        "print(\"--- Debugging clinical_outcomes_df ---\")\n",
        "print(\"Columns in clinical_outcomes_df:\", clinical_outcomes_df.columns)\n",
        "print(\"First 5 rows of clinical_outcomes_df:\\n\", clinical_outcomes_df.head())\n",
        "print(\"---------------------------------------\")\n",
        "\n",
        "\n",
        "# Group by 'Drug' and perform calculations if sufficient data exists\n",
        "for drug_name, group in clinical_outcomes_df.groupby('Drug'):\n",
        "    valid_pfs_values = group['PFS_Numeric'].dropna().tolist()\n",
        "\n",
        "    if len(valid_pfs_values) >= 2: # Need at least 2 values to calculate std deviation and effect size meaningful\n",
        "        mean_pfs = np.mean(valid_pfs_values)\n",
        "        std_pfs = np.std(valid_pfs_values) # Sample standard deviation for effect size calculation\n",
        "\n",
        "        # Avoid division by zero if std_pfs is very small (all values are identical)\n",
        "        if std_pfs < 1e-6: # Using a small threshold instead of exact zero\n",
        "            std_pfs = np.nan # Set to NaN if std is effectively zero, so effect_size becomes NaN\n",
        "\n",
        "        improvement = mean_pfs - GENERAL_HISTORICAL_PFS_BASELINE\n",
        "\n",
        "        # Calculate effect size (Cohen's d)\n",
        "        # Cohen's d = (Mean1 - Mean2) / Pooled_Standard_Deviation\n",
        "        # Here, Mean1 = drug_pfs_mean, Mean2 = historical_pfs, and we're using std_pfs as an estimate for pooled SD.\n",
        "        # This is a simplification; for a proper Cohen's d in future trials, you'd need the SD of the control arm.\n",
        "        # Here, we're using the standard deviation of the observed drug effects as a proxy for variability.\n",
        "\n",
        "        effect_size = np.nan\n",
        "        if not np.isnan(std_pfs):\n",
        "             effect_size = improvement / std_pfs\n",
        "\n",
        "        # Sample size calculation for future trial (if effect size is valid)\n",
        "        estimated_sample_size_per_arm = np.nan\n",
        "        if not np.isnan(effect_size) and effect_size > 0: # Effect size must be positive for power calculation\n",
        "            try:\n",
        "                estimated_sample_size_per_arm = tt_ind_solve_power(\n",
        "                    effect_size=effect_size,\n",
        "                    alpha=0.05,\n",
        "                    power=0.8,\n",
        "                    ratio=1, # Assuming equal sample sizes per arm\n",
        "                    alternative='two-sided' # Assuming two-sided test\n",
        "                )\n",
        "                estimated_sample_size_per_arm = int(np.ceil(estimated_sample_size_per_arm))\n",
        "            except Exception as e:\n",
        "                estimated_sample_size_per_arm = f\"Calculation Error: {e}\"\n",
        "        elif effect_size <= 0:\n",
        "            estimated_sample_size_per_arm = \"No positive effect detected\"\n",
        "\n",
        "\n",
        "        drug_analysis_results.append({\n",
        "            'Drug': drug_name,\n",
        "            'Average PFS (Months)': f\"{mean_pfs:.1f}\",\n",
        "            'PFS Improvement (Months)': f\"{improvement:.1f}\",\n",
        "            'PFS Improvement (%)': f\"{improvement/GENERAL_HISTORICAL_PFS_BASELINE*100:.0f}%\" if GENERAL_HISTORICAL_PFS_BASELINE != 0 else 'N/A',\n",
        "            'Number of PFS data points': len(valid_pfs_values),\n",
        "            'Std Dev of PFS (Months)': f\"{std_pfs:.2f}\" if not np.isnan(std_pfs) else 'N/A',\n",
        "            'Estimated Effect Size (Cohen\\'s d)': f\"{effect_size:.2f}\" if not np.isnan(effect_size) else 'N/A',\n",
        "            'Estimated Sample Size per Arm': estimated_sample_size_per_arm\n",
        "        })\n",
        "    else:\n",
        "        drug_analysis_results.append({\n",
        "            'Drug': drug_name,\n",
        "            'Average PFS (Months)': 'Insufficient data',\n",
        "            'PFS Improvement (Months)': 'Insufficient data',\n",
        "            'PFS Improvement (%)': 'Insufficient data',\n",
        "            'Number of PFS data points': len(valid_pfs_values),\n",
        "            'Std Dev of PFS (Months)': 'Insufficient data',\n",
        "            'Estimated Effect Size (Cohen\\'s d)': 'Insufficient data',\n",
        "            'Estimated Sample Size per Arm': 'Insufficient data'\n",
        "        })\n",
        "\n",
        "analysis_df = pd.DataFrame(drug_analysis_results)\n",
        "\n",
        "print(\"\\n--- Effect Size and Sample Size Calculations Per Drug ---\")\n",
        "print(analysis_df.to_string(index=False))\n",
        "\n",
        "print(\"\\n--- Considerations for Sample Size Calculation ---\")\n",
        "print(f\"  - Historical PFS Baseline: {GENERAL_HISTORICAL_PFS_BASELINE} months (adjust as appropriate for specific cancer types/contexts).\")\n",
        "print(\"  - Effect Size: Calculated as (Drug_PFS - Historical_PFS) / StdDev_Drug_PFS.\")\n",
        "print(\"    * This assumes the standard deviation observed in the collected trials for the drug is representative of future variability.\")\n",
        "print(\"    * For true power calculations, the standard deviation of the control/comparator arm in a future trial is ideally used for Cohen's d.\")\n",
        "print(\"  - Alpha (Significance Level): 0.05 (commonly used, probability of Type I error).\")\n",
        "print(\"  - Power: 0.8 (commonly used, probability of correctly detecting a real effect).\")\n",
        "print(\"  - Ratio: 1 (assumes equal number of patients in each arm of a future trial).\")\n",
        "print(\"  - 'No positive effect detected' means the drug's average PFS was not better than the historical baseline.\")\n",
        "print(\"  - 'Calculation Error' indicates an issue with power calculation (e.g., effect size too small or invalid).\")\n",
        "print(\"\\n--- Drugs with Insufficient PFS Data (needs more data points for analysis) ---\")\n",
        "print(analysis_df[analysis_df['Number of PFS data points'].astype(str).str.contains('Insufficient|0|1')][['Drug', 'Number of PFS data points']].to_string(index=False))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "VtZnIdt8hH5e",
        "outputId": "51776ddb-a601-4663-fa5a-1bdccf18d192"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Using a general historical PFS baseline of 3.0 months for comparison.\n",
            "--- Debugging clinical_outcomes_df ---\n",
            "Columns in clinical_outcomes_df: Index(['Drug', 'PMID', 'Trial Phase', 'Response Rate', 'PFS', 'Journal',\n",
            "       'Year', 'PFS_Numeric'],\n",
            "      dtype='object')\n",
            "First 5 rows of clinical_outcomes_df:\n",
            "         Drug      PMID    Trial Phase            Response Rate  \\\n",
            "0  sorafenib  40556796  Not specified  Reported (see abstract)   \n",
            "1  sorafenib  40547009  Not specified  Reported (see abstract)   \n",
            "2  sorafenib  40542755  Not specified  Reported (see abstract)   \n",
            "3  sorafenib  40521302  Not specified  Reported (see abstract)   \n",
            "4  sorafenib  40519720  Not specified  Reported (see abstract)   \n",
            "\n",
            "                       PFS                                            Journal  \\\n",
            "0  Reported (see abstract)                              Ecancermedicalscience   \n",
            "1             Not reported                            Frontiers in immunology   \n",
            "2  Reported (see abstract)  Asian Pacific journal of cancer prevention : A...   \n",
            "3             Not reported          Cancer drug resistance (Alhambra, Calif.)   \n",
            "4             Not reported                           Translational pediatrics   \n",
            "\n",
            "     Year  PFS_Numeric  \n",
            "0  2025.0          NaN  \n",
            "1  2025.0          NaN  \n",
            "2  2025.0          NaN  \n",
            "3  2025.0          NaN  \n",
            "4  2025.0          NaN  \n",
            "---------------------------------------\n",
            "\n",
            "--- Effect Size and Sample Size Calculations Per Drug ---\n",
            "        Drug Average PFS (Months) PFS Improvement (Months) PFS Improvement (%)  Number of PFS data points Std Dev of PFS (Months) Estimated Effect Size (Cohen's d) Estimated Sample Size per Arm\n",
            "   auranofin    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "cabozantinib    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            " carfilzomib    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            " doxorubicin    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "  epirubicin    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "  everolimus    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "  lenvatinib    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "   nivolumab    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "   pazopanib    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "  pregabalin    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "  ropinirole    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "   sorafenib    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "  tacrolimus    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "  vandetanib    Insufficient data        Insufficient data   Insufficient data                          0       Insufficient data                 Insufficient data             Insufficient data\n",
            "\n",
            "--- Considerations for Sample Size Calculation ---\n",
            "  - Historical PFS Baseline: 3.0 months (adjust as appropriate for specific cancer types/contexts).\n",
            "  - Effect Size: Calculated as (Drug_PFS - Historical_PFS) / StdDev_Drug_PFS.\n",
            "    * This assumes the standard deviation observed in the collected trials for the drug is representative of future variability.\n",
            "    * For true power calculations, the standard deviation of the control/comparator arm in a future trial is ideally used for Cohen's d.\n",
            "  - Alpha (Significance Level): 0.05 (commonly used, probability of Type I error).\n",
            "  - Power: 0.8 (commonly used, probability of correctly detecting a real effect).\n",
            "  - Ratio: 1 (assumes equal number of patients in each arm of a future trial).\n",
            "  - 'No positive effect detected' means the drug's average PFS was not better than the historical baseline.\n",
            "  - 'Calculation Error' indicates an issue with power calculation (e.g., effect size too small or invalid).\n",
            "\n",
            "--- Drugs with Insufficient PFS Data (needs more data points for analysis) ---\n",
            "        Drug  Number of PFS data points\n",
            "   auranofin                          0\n",
            "cabozantinib                          0\n",
            " carfilzomib                          0\n",
            " doxorubicin                          0\n",
            "  epirubicin                          0\n",
            "  everolimus                          0\n",
            "  lenvatinib                          0\n",
            "   nivolumab                          0\n",
            "   pazopanib                          0\n",
            "  pregabalin                          0\n",
            "  ropinirole                          0\n",
            "   sorafenib                          0\n",
            "  tacrolimus                          0\n",
            "  vandetanib                          0\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "\n",
        "# Assuming 'analysis_df' is available from the previous script's effect size calculations.\n",
        "# If not, you'd load it here (e.g., analysis_df = pd.read_csv(\"drug_analysis_results.csv\"))\n",
        "\n",
        "print(\"--- Proposed Confirmatory Trial Designs Per Drug ---\")\n",
        "\n",
        "# Iterate through the analysis_df to propose a trial for each drug\n",
        "for index, row in analysis_df.iterrows():\n",
        "    drug_name = row['Drug']\n",
        "    estimated_sample_size = row['Estimated Sample Size per Arm']\n",
        "\n",
        "    # Convert to int if it's a number, otherwise keep as string/message\n",
        "    if isinstance(estimated_sample_size, (int, float)) and not np.isnan(estimated_sample_size):\n",
        "        estimated_sample_size_display = int(estimated_sample_size)\n",
        "    else:\n",
        "        estimated_sample_size_display = str(estimated_sample_size)\n",
        "\n",
        "    # Generalize the trial arms\n",
        "    proposed_arms = [\n",
        "        f\"{drug_name} + [Optimized Combination/Regimen]\",\n",
        "        \"Current Standard of Care\"\n",
        "    ]\n",
        "    # You could add more sophisticated logic here if you had data on drug combinations\n",
        "    # For instance, if your 'Key Finding' abstracts mentioned common combinations.\n",
        "\n",
        "    trial_design = {\n",
        "        \"Drug for Trial\": drug_name,\n",
        "        \"Primary Endpoint\": \"Progression-Free Survival (PFS)\", # Generalize endpoint\n",
        "        \"Secondary Endpoints\": [\"Objective Response Rate (ORR)\", \"Overall Survival (OS)\", \"Safety and Tolerability\"],\n",
        "        \"Arms\": proposed_arms,\n",
        "        \"Estimated Sample Size (per arm)\": estimated_sample_size_display,\n",
        "        \"Duration\": \"24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\", # Generalized duration\n",
        "        \"Biomarkers\": \"[To be determined based on drug mechanism and disease context]\" # Generalized biomarkers\n",
        "    }\n",
        "\n",
        "    print(f\"\\n--- Trial Design for {drug_name} ---\")\n",
        "    if estimated_sample_size_display in [\"Insufficient data\", \"No positive effect detected\", \"Calculation Error: invalid\", \"Calculation Error\"]:\n",
        "        print(f\"  Cannot propose a definitive sample size due to: {estimated_sample_size_display}\")\n",
        "        print(\"  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\")\n",
        "        # Override sample size and arms for these cases\n",
        "        trial_design[\"Estimated Sample Size (per arm)\"] = \"Requires further investigation\"\n",
        "        trial_design[\"Arms\"] = [f\"{drug_name} + [Investigational]\", \"Comparator\"]\n",
        "    else:\n",
        "        print(f\"  Based on an estimated effect size, a Phase II/III trial for {drug_name} is proposed:\")\n",
        "\n",
        "\n",
        "    for k, v in trial_design.items():\n",
        "        print(f\"  {k}: {v}\")\n",
        "\n",
        "print(\"\\n--- Important Considerations for Automated Trial Design ---\")\n",
        "print(\"  - This is a *template* for trial design based on aggregated data.\")\n",
        "print(\"  - Actual trial design requires deep clinical expertise, regulatory guidance, and specific disease context.\")\n",
        "print(\"  - 'Arms', 'Duration', and 'Biomarkers' are highly generalized and need precise definition based on drug-specific mechanisms and previous trial data (Phase I/II).\")\n",
        "print(\"  - The sample size calculation is based on the average PFS observed and a general historical baseline. Specific trial endpoints and variability will refine this.\")\n",
        "print(\"  - 'Insufficient data' or 'No positive effect detected' means automated sample size calculation was not possible/meaningful for that drug.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "z0L9i3A4knY_",
        "outputId": "9dfbf040-274e-4c30-fe80-246980ca399f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "--- Proposed Confirmatory Trial Designs Per Drug ---\n",
            "\n",
            "--- Trial Design for auranofin ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: auranofin\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['auranofin + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for cabozantinib ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: cabozantinib\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['cabozantinib + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for carfilzomib ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: carfilzomib\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['carfilzomib + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for doxorubicin ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: doxorubicin\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['doxorubicin + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for epirubicin ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: epirubicin\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['epirubicin + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for everolimus ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: everolimus\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['everolimus + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for lenvatinib ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: lenvatinib\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['lenvatinib + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for nivolumab ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: nivolumab\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['nivolumab + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for pazopanib ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: pazopanib\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['pazopanib + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for pregabalin ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: pregabalin\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['pregabalin + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for ropinirole ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: ropinirole\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['ropinirole + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for sorafenib ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: sorafenib\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['sorafenib + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for tacrolimus ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: tacrolimus\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['tacrolimus + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Trial Design for vandetanib ---\n",
            "  Cannot propose a definitive sample size due to: Insufficient data\n",
            "  Further pre-clinical or early-phase clinical data needed before designing a confirmatory trial.\n",
            "  Drug for Trial: vandetanib\n",
            "  Primary Endpoint: Progression-Free Survival (PFS)\n",
            "  Secondary Endpoints: ['Objective Response Rate (ORR)', 'Overall Survival (OS)', 'Safety and Tolerability']\n",
            "  Arms: ['vandetanib + [Investigational]', 'Comparator']\n",
            "  Estimated Sample Size (per arm): Requires further investigation\n",
            "  Duration: 24-36 months accrual + 12-24 months follow-up (typical Phase II/III)\n",
            "  Biomarkers: [To be determined based on drug mechanism and disease context]\n",
            "\n",
            "--- Important Considerations for Automated Trial Design ---\n",
            "  - This is a *template* for trial design based on aggregated data.\n",
            "  - Actual trial design requires deep clinical expertise, regulatory guidance, and specific disease context.\n",
            "  - 'Arms', 'Duration', and 'Biomarkers' are highly generalized and need precise definition based on drug-specific mechanisms and previous trial data (Phase I/II).\n",
            "  - The sample size calculation is based on the average PFS observed and a general historical baseline. Specific trial endpoints and variability will refine this.\n",
            "  - 'Insufficient data' or 'No positive effect detected' means automated sample size calculation was not possible/meaningful for that drug.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "\n",
        "# Assuming 'analysis_df' is available from the previous script's effect size calculations.\n",
        "# If not, you'd load it here (e.g., analysis_df = pd.read_csv(\"drug_analysis_results.csv\"))\n",
        "\n",
        "print(\"--- Estimated Trial Duration and Accrual Per Drug ---\")\n",
        "\n",
        "# General assumptions for a typical clinical trial enrollment\n",
        "# These are broad averages and should be replaced with disease-specific\n",
        "# and site-specific estimates for a real trial design.\n",
        "DEFAULT_ENROLLMENT_PERCENTAGE = 0.05 # e.g., 5% of a general disease population\n",
        "DEFAULT_MONTHLY_ACCRUAL_PER_SITE = 0.5 # e.g., 0.5 patients per site per month\n",
        "DEFAULT_NUMBER_OF_SITES = 20 # Typical number of sites for a multi-center trial\n",
        "\n",
        "# Results storage\n",
        "accrual_duration_results = []\n",
        "\n",
        "for index, row in analysis_df.iterrows():\n",
        "    drug_name = row['Drug']\n",
        "    estimated_sample_size_per_arm = row['Estimated Sample Size per Arm']\n",
        "\n",
        "    # Convert to numeric if possible, otherwise handle as string\n",
        "    if isinstance(estimated_sample_size_per_arm, (int, float)) and not np.isnan(estimated_sample_size_per_arm):\n",
        "        required_total_sample_size = estimated_sample_size_per_arm * 2 # Assuming 2 arms (drug vs control)\n",
        "    else:\n",
        "        # If sample size calculation failed, we cannot estimate duration accurately\n",
        "        accrual_duration_results.append({\n",
        "            'Drug': drug_name,\n",
        "            'Total Sample Size Needed': estimated_sample_size_per_arm,\n",
        "            'Estimated Annual Accrual': 'N/A (Sample size unavailable)',\n",
        "            'Estimated Accrual Rate (Patients/Month)': 'N/A',\n",
        "            'Potential Accrual Duration (Months)': 'N/A',\n",
        "            'Notes': 'Cannot estimate trial duration without a valid sample size.'\n",
        "        })\n",
        "        continue # Skip to the next drug\n",
        "\n",
        "    # --- Accrual Estimation Logic ---\n",
        "    # This is highly simplified and illustrative.\n",
        "    # In a real scenario, you'd need:\n",
        "    # 1. Precise disease prevalence for the specific indication(s) of the drug.\n",
        "    # 2. Number of active sites.\n",
        "    # 3. Site-specific enrollment rates.\n",
        "    # 4. Competing trials.\n",
        "\n",
        "    # Option A: Based on a general patient population (less accurate without specific prevalence)\n",
        "    # Let's assume a large but generic patient pool if we don't have specific prevalence\n",
        "    # Example: If your drugs target various common cancers, annual incidence could be high.\n",
        "    # This is a *very rough* placeholder.\n",
        "    # For a real scenario: `disease_annual_incidence = get_disease_incidence(drug_name)`\n",
        "    # Let's just use an assumed average monthly accrual for a multi-center trial.\n",
        "\n",
        "    # Option B: Based on a fixed monthly accrual rate per site across multiple sites.\n",
        "    # This might be more realistic for early-phase planning without precise epidemiology.\n",
        "    estimated_accrual_per_month = DEFAULT_MONTHLY_ACCRUAL_PER_SITE * DEFAULT_NUMBER_OF_SITES\n",
        "    estimated_annual_accrual = estimated_accrual_per_month * 12\n",
        "\n",
        "    if estimated_accrual_per_month > 0:\n",
        "        potential_accrual_duration_months = required_total_sample_size / estimated_accrual_per_month\n",
        "    else:\n",
        "        potential_accrual_duration_months = np.nan # Cannot accrue if rate is zero\n",
        "\n",
        "    accrual_duration_results.append({\n",
        "        'Drug': drug_name,\n",
        "        'Total Sample Size Needed': f\"{required_total_sample_size:.0f}\",\n",
        "        'Estimated Annual Accrual': f\"{estimated_annual_accrual:.1f} patients/year (based on {DEFAULT_NUMBER_OF_SITES} sites x {DEFAULT_MONTHLY_ACCRUAL_PER_SITE} patients/site/month)\",\n",
        "        'Estimated Accrual Rate (Patients/Month)': f\"{estimated_accrual_per_month:.1f}\",\n",
        "        'Potential Accrual Duration (Months)': f\"{potential_accrual_duration_months:.1f}\" if not np.isnan(potential_accrual_duration_months) else 'N/A (Zero accrual rate)',\n",
        "        'Notes': 'Accrual estimates are highly generalized. Real-world estimates require specific disease prevalence, site capabilities, and trial competitiveness.'\n",
        "    })\n",
        "\n",
        "accrual_duration_df = pd.DataFrame(accrual_duration_results)\n",
        "\n",
        "print(\"\\n--- Summary of Accrual and Duration Estimates Per Drug ---\")\n",
        "print(accrual_duration_df.to_string(index=False))\n",
        "\n",
        "print(\"\\n--- Important Considerations for Accrual and Duration Estimates ---\")\n",
        "print(\"  - **Disease Prevalence:** The most critical missing piece for accurate estimates. You need the annual incidence or prevalence of the specific disease(s) targeted by each drug.\")\n",
        "print(f\"  - **Assumed Accrual Rate:** Currently based on a default of {DEFAULT_MONTHLY_ACCRUAL_PER_SITE} patients/site/month across {DEFAULT_NUMBER_OF_SITES} sites.\")\n",
        "print(\"    * This should be replaced with realistic estimates based on historical site performance and patient pool analysis.\")\n",
        "print(\"  - **Trial Complexity:** More complex trials (e.g., with specific biomarker requirements) often have slower accrual.\")\n",
        "print(\"  - **Competing Trials:** Many trials for similar indications can dilute the patient pool.\")\n",
        "print(\"  - **Patient Dropout:** The sample size from the previous step accounts for statistical power, but actual enrollment needs to consider screen failures and dropouts during accrual.\")\n",
        "print(\"  - **Follow-up Duration:** Total trial duration is accrual duration + minimum follow-up duration for primary endpoint.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NaYeA5ZjrZ6r",
        "outputId": "92adc3b5-ae55-4e0a-ca12-d01dd07dfeeb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "--- Estimated Trial Duration and Accrual Per Drug ---\n",
            "\n",
            "--- Summary of Accrual and Duration Estimates Per Drug ---\n",
            "        Drug Total Sample Size Needed      Estimated Annual Accrual Estimated Accrual Rate (Patients/Month) Potential Accrual Duration (Months)                                                       Notes\n",
            "   auranofin        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "cabozantinib        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            " carfilzomib        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            " doxorubicin        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "  epirubicin        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "  everolimus        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "  lenvatinib        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "   nivolumab        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "   pazopanib        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "  pregabalin        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "  ropinirole        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "   sorafenib        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "  tacrolimus        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "  vandetanib        Insufficient data N/A (Sample size unavailable)                                     N/A                                 N/A Cannot estimate trial duration without a valid sample size.\n",
            "\n",
            "--- Important Considerations for Accrual and Duration Estimates ---\n",
            "  - **Disease Prevalence:** The most critical missing piece for accurate estimates. You need the annual incidence or prevalence of the specific disease(s) targeted by each drug.\n",
            "  - **Assumed Accrual Rate:** Currently based on a default of 0.5 patients/site/month across 20 sites.\n",
            "    * This should be replaced with realistic estimates based on historical site performance and patient pool analysis.\n",
            "  - **Trial Complexity:** More complex trials (e.g., with specific biomarker requirements) often have slower accrual.\n",
            "  - **Competing Trials:** Many trials for similar indications can dilute the patient pool.\n",
            "  - **Patient Dropout:** The sample size from the previous step accounts for statistical power, but actual enrollment needs to consider screen failures and dropouts during accrual.\n",
            "  - **Follow-up Duration:** Total trial duration is accrual duration + minimum follow-up duration for primary endpoint.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Define your list of candidate drugs (lowercase for consistency)\n",
        "drug_list = [\n",
        "    \"sorafenib\", \"lenvatinib\", \"cabozantinib\", \"vandetanib\", \"everolimus\",\n",
        "    \"pazopanib\", \"nivolumab\", \"doxorubicin\", \"epirubicin\", \"ropinirole\",\n",
        "    \"pregabalin\", \"tacrolimus\", \"auranofin\", \"carfilzomib\"\n",
        "]\n",
        "\n",
        "# Use pubmed_df which contains 'Title' and 'Abstract'\n",
        "pubmed_df[\"Title_lower\"] = pubmed_df[\"Title\"].str.lower()\n",
        "pubmed_df[\"Abstract_lower\"] = pubmed_df[\"Abstract\"].str.lower()\n",
        "\n",
        "# Initialize drug score dictionary\n",
        "drug_scores = {}\n",
        "\n",
        "# Count how many times each drug appears in titles or abstracts\n",
        "for drug in drug_list:\n",
        "    count = pubmed_df[\"Title_lower\"].str.contains(drug, na=False).sum() + pubmed_df[\"Abstract_lower\"].str.contains(drug, na=False).sum()\n",
        "    drug_scores[drug] = count\n",
        "\n",
        "# Convert to DataFrame for easy sorting and display\n",
        "score_df = pd.DataFrame(list(drug_scores.items()), columns=[\"Drug\", \"Frequency\"])\n",
        "score_df = score_df.sort_values(by=\"Frequency\", ascending=False).reset_index(drop=True)\n",
        "\n",
        "# Display the ranked list of drugs\n",
        "print(score_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Lcuxdu3wyINg",
        "outputId": "bcdf73e1-2382-4dce-ce94-35e16f5666cd"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "            Drug  Frequency\n",
            "0     lenvatinib         28\n",
            "1    doxorubicin         14\n",
            "2      sorafenib          8\n",
            "3     vandetanib          3\n",
            "4      auranofin          2\n",
            "5      pazopanib          2\n",
            "6     everolimus          1\n",
            "7   cabozantinib          1\n",
            "8      nivolumab          1\n",
            "9     epirubicin          0\n",
            "10    ropinirole          0\n",
            "11    pregabalin          0\n",
            "12    tacrolimus          0\n",
            "13   carfilzomib          0\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "\n",
        "# Select top N drugs for visualization\n",
        "top_n = 10\n",
        "top_drugs = score_df.head(top_n)\n",
        "\n",
        "# Bar Chart\n",
        "plt.figure(figsize=(10, 6))\n",
        "plt.barh(top_drugs[\"Drug\"], top_drugs[\"Frequency\"], color='skyblue')\n",
        "plt.xlabel(\"Frequency of Mentions\")\n",
        "plt.title(f\"Top {top_n} Frequently Mentioned Drugs in ATC Literature\")\n",
        "plt.gca().invert_yaxis()  # Highest on top\n",
        "plt.grid(axis='x', linestyle='--', alpha=0.7)\n",
        "plt.tight_layout()\n",
        "plt.show()\n",
        "\n",
        "# Pie Chart\n",
        "plt.figure(figsize=(8, 8))\n",
        "plt.pie(\n",
        "    top_drugs[\"Frequency\"],\n",
        "    labels=top_drugs[\"Drug\"],\n",
        "    autopct='%1.1f%%',\n",
        "    startangle=140,\n",
        "    colors=plt.cm.tab20.colors\n",
        ")\n",
        "plt.title(f\"Distribution of Top {top_n} Drug Mentions in Literature\")\n",
        "plt.axis('equal')  # Equal aspect ratio ensures circular pie chart\n",
        "plt.tight_layout()\n",
        "plt.show()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "AX-WNhVByehI",
        "outputId": "3c29fbc4-6191-4337-bb6b-be590c7c2ca6"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 800x800 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    }
  ]
}